Newsroom

study demonstrates selective targeting of misfolded tdp-43 with relevance to amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease victoria, british columbia--(business wire)-- mindwalk holdings corp. (“mindwalk” or the “company”) (nasdaq: hyft) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic tdp-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease. this achievement, generated through mindwalk’s integrated discovery engines and research ecosystem, demonstrates the company’s ability to discriminate with structural precision between toxic protein conformations and their essential, healthy counterparts, a long-standing challenge in neurodegenerative disease drug development. by defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, mindwalk is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets. “this discovery is a direct validation of our platform strategy,” said dr. jennifer bath, president and chief executive officer of mindwalk. “we are not just discovering antibodies. we are identifying the disease-defining protein state and translating that insight into selective, validated assets with traceable biological evidence behind them. this is what platform-driven execution looks like in debilitating, life-threatening disease.” mindwalk has demonstrated its ability to generate disease-defining biological assets through the creation of monoclonal antibodies and intrabodies that selectively recognize misfolded, pathogenic tdp-43, a protein implicated in nearly all als cases and a significant portion of ftd and alzheimer’s disease cases. the defining feature of this work is selectivity: the ability to distinguish toxic protein conformations from their healthy counterparts, a key determinant of downstream development risk in neurodegenerative drug programs. beyond the specific biology, this work provides external validation of mindwalk’s platform capabilities in a client-driven setting. it demonstrates the company’s ability to systematically identify and characterize disease-driving protein states and translate that understanding into selective, evidence-linked biological assets. strategically, this strengthens mindwalk’s position as a trusted discovery partner for complex neurodegenerative programs and supports expanded opportunities for future collaborations, repeat engagements, and broader application of its platform across similarly challenging disease areas. “every molecule we characterize today strengthens our evidence base for what defines disease and what distinguishes healthy biology,” added dr. bath. “that compounding, evidence-linked learning is what defines a truly bio-native platform.” the full scientific study, “rational generation of monoclonal antibodies and intrabodies selective for pathogenic tdp-43,” is available on biorxiv (doi: 10.1101/2025.06.10.658846). about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by its patented hyft® technology and lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with a fully integrated wet-lab. the platform enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics to convert insight into validated candidates with speed and precision. forward looking statement this press release contains forward-looking statements within the meaning of applicable securities laws. forward-looking statements include statements regarding the significance of the discovery and validation described in this release, the company’s discovery capabilities and platform performance, the potential relevance or application of the monoclonal antibodies and intrabodies referenced, the ability to identify and characterize disease-driving protein states, the potential translation of preclinical findings into future research or development programs, and potential future collaboration, partnering, licensing, or commercialization opportunities. forward-looking statements are based on management’s current expectations and assumptions as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. these risks and uncertainties include, but are not limited to, the preliminary nature of scientific findings reported in a preprint that has not undergone peer review; the possibility that subsequent peer review, additional experiments, or further analysis may produce different or contrary results; scientific and technical challenges inherent in drug discovery and development; uncertainties regarding reproducibility, selectivity, safety, pharmacology, and manufacturability; uncertainties regarding the translation of preclinical findings into clinical outcomes; regulatory requirements and approval processes; the company’s reliance on third-party collaborators, clients, and partners; intellectual property risks and uncertainties; competitive developments; market and macroeconomic conditions; and the company’s ability to execute its strategy, secure resources, and manage growth. except as required by law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

validated across influenza a and influenza b, including h3n2 subclade k and zoonotic influenza a subtypes h5, h7, h9 austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq:hyft) (“mindwalk” or the “company”), a bio-native ai therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. using its patented hyft® deep data technology, mindwalk identified a functional pattern embedded in influenza biology that remains intact beneath surface-level genetic change. when mindwalk examines what does not change, it is not referring to conserved genetic sequences. it refers to preserved biological constraints; the biophysical requirements influenza must satisfy for infection. influenza remains a major global health threat because influenza viruses continually alter immune-exposed regions of surface proteins, eroding durable protection and forcing reactive vaccine redesign. current u.s. surveillance reflects unusually high influenza activity, described in public reporting as the highest level in approximately 25 years. why influenza keeps beating conventional vaccines most influenza research relies on tracking genetic variation. researchers align sequences, score similarity, and catalog mutations. these methods support surveillance, yet they often miss deeper functional constraints because they operate at the level influenza changes readily. mindwalk’s hyft® pattern technology works without sequence alignment, capturing multi-dimensional functional fingerprints that encode geometry, stability, and biophysical constraints. this reveals functional logic that remains stable even when sequence variation obscures it. this is a layer influenza is constrained from altering without loss of core function required for infection. validation across influenza a subtypes and influenza b lineages using its proprietary hyft pattern framework, mindwalk evaluated the identified functional constraint across influenza a and influenza b datasets spanning multiple hosts. the hyft-defined pattern was confirmed across currently circulating influenza a viruses, including viruses classified within h3n2 subclade k, a genetic subgroup under active global surveillance. the same strict functional pattern was also observed across avian influenza a datasets spanning subtypes h5, h7, and h9, indicating preservation of this constraint across both human and avian influenza backgrounds. mindwalk expanded this analysis beyond influenza a to include influenza b, evaluating representative references from both influenza b lineages, victoria and yamagata, and again observed the same strict hyft-defined functional pattern. in addition, assessment of a representative swine-origin influenza a h1n1 dataset yielded the same result. taken together, mindwalk has now identified this conserved hyft pattern across: influenza a in human datasets, including h3n2 and h3n2 subclade k influenza a in avian datasets, spanning subtypes h5, h7, and h9 influenza a in swine-associated datasets, including h1n1 influenza b across both victoria and yamagata lineages across the influenza datasets evaluated to date, mindwalk has not observed a different way for influenza to meet this functional requirement within the constraints analyzed. these results support the conclusion that the identified pattern reflects an evolutionary constraint shared across influenza a and influenza b, rather than a strain-specific or sequence-dependent feature. “influenza constantly rewrites its genetic script, but it remains tightly constrained by the physics required for infection,” said jennifer bath, ph.d., ceo of mindwalk. “our hyft technology allows us to identify those constraints and design directly against them.” from discovery to biological reasoning and rational vaccine design this advance builds directly on mindwalk’s prior work in rational vaccine design and further supports its bio-native ai and deep data approach. rather than predicting outcomes from incomplete inputs, mindwalk’s lensai™ platform, using the core hyft technology, captures and reasons over biological context, linking sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system. by reasoning directly from biological constraints, mindwalk aims to improve decision quality, reduce downstream failure, and increase the expected value of drug discovery programs. “influenza has been studied for decades, yet researchers kept looking at what changes instead of what does not,” said dirk van hyfte md, phd, chief technology officer of mindwalk. “hyft technology let us step outside sequence thinking and identify a functional constraint influenza must preserve for infection. once you see that layer, the problem stops being about prediction and starts being about design.” influenza program development and out-licensing strategy mindwalk intends to advance its influenza program through a phased, capital-efficient development pathway built around program-level segregation. platform-derived programs are structured as standalone development portfolios, allowing capital, risk, and decision-making to align with each individual asset while preserving the integrity of mindwalk’s core discovery platform. under this approach, the influenza program will progress through additional pre-clinical validation and ind-enabling work within its own dedicated portfolio. this structure is designed to support focused investment, clear value inflection points, and efficient governance as the program advances. following ind-enabling activities and sufficient pre-clinical de-risking, mindwalk plans to out-license the influenza program or enter into strategic development partnerships with global pharmaceutical companies with the scale and infrastructure to advance late-stage development and commercialization. mindwalk also expects to support discussions regarding potential strategic investments and other financing alternatives for the program. about mindwalk mindwalk is a bio-native ai therapeutic research and technology company. through its lensai platform and patented hyft technology, mindwalk generates proprietary biological pattern intelligence designed to support rational vaccine and therapeutic discovery. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “seeks,” “potential,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding the company’s influenza research findings and their interpretation; the identification, characterization, and relevance of hyft patterns; the scope of the company’s universal influenza program, including intended breadth across influenza a and influenza b and across seasonal and zoonotic strains; the initiation, design, timing, and results of planned wet-lab validation activities; the ability to translate the reported findings into immunogens, vaccine candidates, or other development assets; the ability to demonstrate immune accessibility, immunogenicity, safety, breadth, and durability in preclinical studies and, if pursued, clinical settings; the timing and outcome of future development decisions; and the company’s ability to pursue, structure, or complete strategic investments, financing alternatives, collaborations, partnering arrangements, or licensing transactions related to the program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. forward-looking statements involve known and unknown risks, uncertainties, and other factors that cause actual results, performance, or achievements to differ materially from those expressed or implied. these factors include, among others: the preliminary nature of computational analyses and in silico observations; limitations in available data, sampling, and surveillance inputs; the risk that laboratory studies do not replicate or validate the reported findings; uncertainty regarding whether the identified pattern is immune accessible or yields protective immune responses; risks inherent in vaccine discovery and development, including antigen design, formulation, delivery, manufacturability, stability, and scale-up; the risk that a candidate does not demonstrate acceptable safety, tolerability, immunogenicity, breadth, or durability in preclinical studies or clinical settings; the risk of viral evolution and immune escape that reduces effectiveness; regulatory requirements and uncertainties, including requirements for preclinical packages and clinical trial design; dependence on third-party manufacturers, laboratories, collaborators, suppliers, and other service providers; the need for additional capital and the availability, terms, and timing of strategic investments or other financing alternatives; the ability to enter, maintain, and enforce collaborations, partnering arrangements, or licensing transactions on acceptable terms; intellectual property risks, including the ability to obtain, maintain, defend, and enforce patent and other proprietary rights; competitive developments; and broader economic, market, geopolitical, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), bio-native ai company today announces the appointment of industry veteran r. scott areglado as chief financial officer (cfo), effective october 20, 2025. “scott’s extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team,” said dr. jennifer bath, mindwalk ceo. “his proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our bio-native ai platform globally.” mr. areglado brings more than 25 years of financial leadership experience across the healthcare, life sciences, and technology sectors, including extensive expertise in corporate finance, strategic planning, capital markets, and investor relations for publicly traded companies. he has a consistent record of strengthening financial operations, driving revenue growth, and supporting transformative transactions that deliver shareholder value. most recently, mr. areglado served as chief financial officer of brainsway ltd. (nasdaq: bway), a global medical device leader in interventional psychiatry. there, he helped redefine corporate strategy and led eight consecutive quarters of revenue growth while enhancing financial discipline and transparency. he also expanded analyst coverage and investor engagement, strengthening the company’s capital market presence. before joining brainsway, mr. areglado was chief financial officer at icad, inc. (nasdaq: icad), a medical technology company specializing in ai-driven cancer detection and therapy solutions. during his tenure, he successfully led multiple financings totaling more than $50 million, executed strategic partnerships, and supported a series of acquisitions that advanced the company’s product portfolio and market position. earlier in his career, mr. areglado held senior financial roles at amicas, inc. (nasdaq: amcs) and several emerging growth technology companies, where he developed deep expertise in sec reporting, m&a integration, and operational transformation. he began his career in public accounting and holds an mba from babson college and a bba in accounting from the university of massachusetts amherst. mr. areglado added, “mindwalk represents a unique opportunity to apply data-driven financial leadership in support of an organization poised to redefine how ai is applied in life sciences. i am excited to join the team and help advance both our strategic and financial goals as we build long-term value for shareholders.” annual general meeting results and board update mindwalk also announced the results of its 2025 annual general meeting of shareholders, held on october 9, 2025. each of dr. jennifer bath, jon lieber, and dirk witters was elected to the company’s board of directors, and davidson & company llp was re-appointed as auditor for the ensuing fiscal year. in accordance with the company’s majority voting policy, mr. kamil isaev, having received approximately 32% of votes in favor and 68% withheld for his re-election, has tendered his resignation to the board. the board has accepted mr. isaev’s resignation, effective immediately, and wishes to thank him for his valuable contributions to mindwalk’s transformation into a bio-native ai leader. mindwalk will file the complete voting results of the 2025 agm on sedar+ and on form 6-k with the u.s. securities and exchange commission. the board is initiating a search process to fill the resulting vacancy and will provide an update once a successor has been appointed, consistent with the company’s governance framework about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company today announced the appointment of industry veteran thomas w. lynch, ph.d. as chief business officer (cbo), effective october 20, 2025. “tom’s combination of biotech depth and software commercialization expertise directly supports mindwalk’s next path of growth,” said dr. jennifer bath ceo of mindwalk. “as we expand the reach of our hyft-powered deep data platform across pharma and biotech markets worldwide, tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value.” dr. lynch is an accomplished industry leader with over two decades of experience focused at the intersection of biotechnology and software innovation. dr. lynch has a strong track record in scaling global commercial organizations, launching high-impact products, and driving market adoption of advanced software and data platforms. his career spans technical sales, client services, and business development, where he has consistently delivered growth by combining deep scientific understanding with disciplined commercial execution. most recently, dr. lynch served as director of technical sales & scientific support at aldevron, where he built and led a new global commercial team, aligning strategies with scientific innovation and client needs. prior to that, as vice president of global sales and client services, dr. lynch spearheaded key initiatives including the introduction of clinical mrna manufacturing services and strategic account expansion that materially advanced aldevron’s market position. these efforts were instrumental in accelerating growth and positioning aldevron for its $9.6b acquisition by danaher life sciences in 2021. earlier in his career, dr. lynch led global commercial operations at dnastar, overseeing sales, distribution, and technical support while successfully launching software products that advanced protein structure prediction and analysis, such as novafold powered by i-tasser. his achievements underscore a proven ability to successfully bring complex scientific software and data platforms to market. dr. lynch also serves on the board of bioforward, wisconsin’s leading biohealth association, where he helped drive industry collaboration, education, and legislative initiatives across wisconsin’s biohealth sector. dr. lynch added: “mindwalk sits at the frontier of ai-native data intelligence in life sciences. i am excited to help accelerate the company’s growth trajectory by translating its powerful technology into solutions that drive measurable value for customers, partners, and investors alike.” mindwalk’s appointment of dr. lynch marks another step in executing its commercial strategy to broaden adoption of its bio-native ai platform, positioning the company to capture a growing share of the multibillion-dollar life sciences data analytics market. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding mindwalk’s appointment of dr. thomas w. lynch as chief business officer; the expected impact of this appointment on the company’s commercial strategy and growth trajectory; the scalability and adoption of mindwalk’s hyft® technology and lensai™ platform; and the company’s ability to expand its bio-native ai solutions across pharmaceutical and biotechnology markets. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks related to the execution of commercial and strategic initiatives; challenges in scaling ai-enabled software adoption in complex enterprise environments; scientific or technical development risks; market acceptance of the company’s technologies; competitive pressures; intellectual property protection; and general economic, regulatory, or geopolitical conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f for the fiscal year ended april 30, 2025, available on the company’s profiles at www.sedarplus.ca and www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

company builds on earlier glp-1 success with breakthrough ai-led insights into aging biology -- targeting the widely projected $60b longevity therapeutics market hyft®-driven discovery supports co-administration of mindwalk’s proprietary companion therapeutic with the company’s glp-1 receptor agonist austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company, today announced a major advancement of its ai-designed glp-1 therapeutics program. new insights from the company’s lensai™ platform reveal a previously unrecognized connection between glp-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. the findings support a first-in-class dual-pathway regimen in which mindwalk’s proprietary companion therapeutic is co-administered with its glp-1 receptor agonists (glp-1ras) to engage both mechanisms in concert. to the company’s knowledge, no approved or marketed drugs use this regimen. the companion therapeutic is a mindwalk-exclusive asset and is not a repurposed or co-branded product. this strategic evolution builds directly on mindwalk’s earlier success designing glp-1ras entirely in silico and positions the company to address the high-growth longevity therapeutics market, widely projected to exceed $60 billion by 2030. key takeaways expansion builds directly on mindwalk’s previously announced glp-1ra success. lensai™ identifies a complementary longevity-linked pathway and guides a proprietary companion therapeutic designed to be administered alongside mindwalk’s glp-1ras. regimen is first-in-class to the company’s knowledge and engineered for preventive, chronic use. strategy aims to enhance efficacy, durability, and long-term adherence. platform enables repeatable, in silico design and optimization of combination therapeutics in high-growth markets. redefining the scope of glp-1 therapeutics with bio-native ai using hyft®, mindwalk’s patented first-principles discovery engine, lensai™ mapped conserved biological patterns that link glp-1 signaling to adaptive resilience in metabolism, inflammation balance, and cellular stress response. in parallel, lensai™ identified a complementary regulatory node—kept undisclosed while validation and protection activities proceed—that interfaces with these same longevity-relevant processes. together, these insights form the basis of a novel dual-pathway regimen designed to maintain the benefits of glp-1 while broadening impact on healthspan outcomes. unlike traditional black-box ai tools, lensai™ provides explainability, biological traceability, and full lineage tracking designed to support regulatory review of ai-informed decisions throughout discovery and development. “glp-1 drugs have already transformed diabetes and obesity care, but their potential as healthspan medicines is only beginning to be recognized,” said dr. jennifer bath, ceo of mindwalk. “by applying hyft® and lensai™, we are not simply iterating on existing drugs—we are uncovering first principles that enable the design of safe, durable glp-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway. to our knowledge, this represents a new route in longevity medicine and a direct evolution of our earlier success, showing how our bio-native ai platform creates repeatable, high-impact programs in preventive health.” scientific foundation: a confidential, complementary longevity pathway leveraging mindwalk’s patented hyft® patterns—universal biological fingerprints that encode conserved sequence-structure-function relationships—lensai™ integrated sequence models, structural predictions, and knowledge-graph reasoning to highlight a second, non-overlapping pathway that operates alongside glp-1 in maintaining cellular robustness. while specific target details remain undisclosed, this hyft-anchored analysis indicates that coordinated engagement of both mechanisms may help sustain high-quality signaling, moderate stress responses, and reinforce metabolic balance over time—key aims for healthspan-oriented, chronic therapies. the regimen is engineered to sustain high-quality glp-1 signaling while engaging complementary resilience processes implicated in healthy aging. mindwalk has initiated intellectual-property protection around the companion therapeutic and regimen design. recent progress and forward strategy earlier this year, mindwalk reported that its ai-designed glp-1 peptides matched or exceeded semaglutide—a global market leader—in receptor activation assays. those sequences were discovered, selected, and optimized entirely in silico using lensai™, marking a major milestone in scalable, data-driven drug discovery. building on that foundation, the company is now advancing a dual-pathway program that includes: ai-optimized, long-acting glp-1 analogs for durable, patient-friendly dosing; a mindwalk-exclusive companion therapeutic directed at a longevity-linked, non-overlapping pathway for regimen-level co-administration; in silico exploration of dose, schedule, and sequence design to inform preclinical evaluation of the proprietary combination; incorporation of aging biomarkers and healthspan endpoints into discovery and preclinical prioritization; and mindwalk expects to provide updates on lead selection for the companion therapeutic, preclinical combination design parameters, and potential development paths for the regimen in the coming quarters. “this announcement reflects the scalability of mindwalk’s bio-native ai platform and its ability to address high-value therapeutic categories with speed and scientific rigor,” said dr. dirk van hyfte, cto of mindwalk bv. platform scalability: beyond a single mechanism the dual-pathway glp-1 program exemplifies the scalability and repeatability of mindwalk’s approach. the same hyft®-driven framework is being applied across additional therapeutic areas—including oncology, immunology, and vaccine design—enabling a multi-program pipeline built from a single, explainable ai foundation. mindwalk’s platform is used by leading biopharma partners and supports multi-program discovery across modalities. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s expansion of its glp-1 receptor agonist program toward longevity and healthspan medicine; the anticipated benefits of applying hyft® technology and the lensai™ platform to metabolic and aging biology; the development and potential of a co-administered proprietary companion therapeutic engaging a complementary longevity pathway; the potential for next-generation glp-1 therapeutics to achieve outcomes beyond glycemic control; and the scalability and repeatability of the company’s bio-native ai approach across therapeutic areas. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks inherent in drug discovery and development; challenges in validating preclinical findings in clinical settings; regulatory approval requirements and uncertainties; market adoption dynamics in longevity and metabolic medicine; competitive developments in glp-1 and adjacent therapeutic classes; intellectual property protection; reliance on third-party partners; and broader economic, geopolitical, or regulatory shifts. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

an evolution in name, structure, and strategy reflecting the company’s ai-driven platform and bio-native discovery vision austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), immunoprecise antibodies ltd. and its subsidiaries (biostrand and talem) today announced a unification under a single corporate brand, mindwalk, and a change of its nasdaq ticker symbol to hyft. the new identity conveys the company’s evolution into a bio-native ai platform business built at the intersection of ai, multi-omics data, and advanced laboratory research. “today is an evolutionary step forward,” said dr. jennifer bath, president and chief executive officer of mindwalk. “inspired by darwin’s thinking path, mindwalk is about seeing what others can’t—patterns hidden in biology that point to better medicines. our role is to convert that insight into impact, uniting science, computation, and responsible experimentation to change the pace of care.” mindwalk: a new era in bio-native ai-powered discovery inspired by charles darwin’s daily walks along his “thinking path” — where he questioned convention and advanced new theories — mindwalk carries that spirit forward. it represents a modern extension of that philosophy: a transformative, pattern-seeking journey through the complexity of biology, powered by the combined strengths of ai, data and advanced lab research. now operating as a bio-native ai company, mindwalk reimagines discovery by intelligently integrating data across formats and disciplines—turning information into dynamic biological meaning. by making biological diversity computable, mindwalk unifies this data into a single, structured system that accelerates discovery with depth and direction. at the core of this transformation is the company’s lensai™ platform powered by hyft® technology, built to redefine how biologics are discovered and developed. drug discovery, unified—from idea to impact. this brand evolution is also a business transformation. mindwalk is expanding beyond specialized wet-lab services to commercialize an intelligence-platform model—amplifying discovery, enabling recurring saas offerings, creating generative asset opportunities, and supporting scalable partnerships across the pharmaceutical ecosystem. key business highlights: unified brand identity: immunoprecise antibodies (ipa) together with its subsidiaries biostrand and talem are now unified as mindwalk, a single brand under the umbrella of mindwalk holdings corp. business model shift: transitioning from standalone wet-lab services to an integrated, scalable platform company model — launching daas, saas offerings, enhancing asset generation, and enabling large-scale partnerships new nasdaq ticker: “hyft” — replacing “ipa” to reflect the foundational role of hyft ® technology in the company’s ai stack “mindwalk is the first to make biological diversity truly computable — integrating multi-modal data into a structured system that drives insight with clarity, speed, and depth,” added dr. bath. for more information visit: mindwalkai.com about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s name change and ticker symbol transition to “hyft,” the anticipated benefits of rebranding under the mindwalk ai identity, projected scalability and adoption of the hyft® technology and lenai™ platform, and the company’s strategic shift toward a unified, ai-native discovery model. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: operational challenges in executing the rebrand and technology consolidation; risks associated with platform scalability and ai integration; scientific or technical validation hurdles; evolving market adoption dynamics in the saas and biologics r&d sectors; economic, geopolitical, or regulatory shifts; and customer or partner response to the new corporate structure. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mab) responses. austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. building on its june announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its lensai™ platform powered by patented hyft® technology, the company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralization analysis. the manufactured product will be used in proprietary immunization protocols at ipa’s canadian facility. these studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mab) responses—a crucial step toward translational development. “this is the natural next step in our journey from ai discovery to real-world validation,” said dr. jennifer bath, ceo of immunoprecise. “we’ve shown that hyft technology can identify vaccine targets that others miss — unique targets that are conserved, specific, and immunologically relevant. now we’re now moving into manufacturing and live immunization studies, where the question becomes: can this target elicit a powerful and protective antibody response? this is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases.” the science behind the step: ai discovery → manufacturing: hyft-guided analysis revealed a discontiguous dengue epitope conserved across all four virus serotypes. validated safety & immunogenicity: in silico screens confirmed immune activation potential (b- and t-cell responses), structural stability, and comprehensive safety against host proteomes. now entering immunization studies: the product is being synthesized and will be used in rabbit models to assess whether it elicits specific monoclonal antibodies — an essential proof point for vaccine development. a platform approach, not just a vaccine: this progression highlights ipa’s end-to-end advantage: combining ai-native discovery with in-house wet-lab validation. with regulators like the u.s. fda encouraging predictive, human-relevant approaches that reduce reliance on animal testing, immunoprecise’s in silico-to-in vivo workflow represents a forward-looking model for next-generation vaccine r&d. by applying the same methodology across pathogens, ipa is positioning its lensai/hyft platform as a versatile discovery engine — not only for dengue, but also for other infectious diseases and immuno-oncology targets. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutics company focused on the discovery and development of next-generation biologics. the company combines scientific expertise with proprietary technologies—such as its lensai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. ipa supports global partners in advancing novel therapeutics, diagnostics, and translational research. for more information, visit www.ipatherapeutics.com. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s advancement of its universal dengue vaccine initiative, the anticipated benefits of its proprietary hyft® and lensai™ platforms, the potential for its vaccine candidate to generate protective monoclonal antibody responses, and the broader applicability of its ai-native discovery platforms to infectious diseases and immuno-oncology. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks inherent in preclinical studies and vaccine development; uncertainties in manufacturing, immunization, and virus neutralization testing; execution risks related to ai-driven discovery and translational validation; the pace and accuracy of scientific and technological innovation; competitive dynamics in biologics and vaccine r&d; customer and partner adoption rates; and shifts in economic, market, or regulatory conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its netherlands-based subsidiary, immunoprecise antibodies (europe) b.v. (“ipa europe”), to avs bio for a total enterprise value of $12 million usd. avs bio, a portfolio company of arlington capital partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. the transaction generated $11.7 million usd in net proceeds on a cash-free, debt-free basis. this transaction marks a meaningful step in ipa’s strategic refinement—streamlining its operational footprint, strengthening its balance sheet, and allowing the company to concentrate resources on its most impactful growth areas. the proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs. “this transaction delivers strong value to ipa and our investors,” said dr. jennifer bath, president and ceo of immunoprecise antibodies ltd. “it reflects our disciplined strategy to focus resources on our ai-based software as a service (saas) platform—where we’re combining scientific expertise with advanced technologies to accelerate modern biologics discovery. we’re proud of the business we’ve built in the netherlands and confident it will continue to thrive under avs bio’s ownership.” ipa’s global operations span biologics discovery, engineering, and characterization, supported by lensai™, the company’s proprietary platform powered by hyft® multi-omics technology. lensai helps unify and interpret complex biological data, enabling more integrated insights and smarter decisions across the discovery and development process. by harmonizing data across modalities, the platform supports faster identification of opportunities and reduces inefficiencies that typically slow biologics innovation. the sale was conducted through a competitive, arm’s-length process. a 12-month transition services agreement (tsa) will provide continuity across key functions during the transition. ipa holds no material ongoing relationship with avs bio or its affiliates beyond the scope of the transaction. edgemont partners served as exclusive financial advisor to ipa. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutics company focused on the discovery and development of next-generation biologics. the company combines scientific expertise with proprietary technologies—such as its lensai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. ipa supports global partners in advancing novel therapeutics, diagnostics, and translational research. for more information, visit www.ipatherapeutics.com. about avs bio headquartered in norwich, ct, avs bio is a global provider of specific pathogen-free (spf) laboratory products and services that support the development and manufacture of vaccines, therapeutics, and biologics. the company supplies leading manufacturers with critical bioprocessing inputs including spf eggs, antigens, and antibodies, and also offers diagnostic testing and gmp support services. avs bio operates more than 20 facilities across north america and europe and is a portfolio company of arlington capital partners. for more information, visit www.avsbio.com. about arlington capital partners arlington capital partners is a washington, d.c.-area private investment firm specializing in government-regulated industries. the firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. since its inception in 1999, arlington has invested in over 175 companies and is currently investing out of its $3.8 billion fund vi. for more information, visit arlington’s website at www.arlingtoncap.com and follow arlington on linkedin. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the anticipated benefits of the divestiture of ipa europe, the company’s strategic focus on its ai-native platforms, projected scalability and market adoption of its lensai™ platform, and the impact of reinvestment into data-driven, biologics discovery technologies. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: operational challenges in transitioning the divested business; execution risks related to ai-driven platform scaling; the pace and accuracy of scientific and technological innovation; changes in competitive dynamics within saas and biologics r&d markets; customer adoption rates; and shifts in economic, market, or regulatory conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com avs bio & arlington capital partners ryan fitzgibbon pro-arlington@prosek.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a bio-native ai pioneer operating where techbio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its lensai™ immunogenicity screening can reliably predict anti-drug-antibody (ada) risk for therapeutic proteins before they enter animal studies or human trials. “ada-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,” said dr. jennifer bath, president & ceo, ipa. “with lensai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.” late‑stage ada failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑mhc ii binding across a few dozen hla alleles—leaving large swaths of immune diversity untested and immunogenic “self/non‑self” checks largely unaddressed. lensai’s hyft‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. it evaluates nearly 900 hla variants and performs a whole‑proteome “humanness” scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. by revealing design‑level fixes before expensive animal studies or repeat gmp production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. study highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ada dataset to predict immunogenicity risk single composite score tracks clinical reality – enables reliable ada incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ada in patients). the discriminative capability is very powerful as indicated by an auc=0.92. alignment-free, hyft-powered engine – the proprietary screening algorithm combines state-of-the-art mhc ii binding with ipa’s proprietary hyft® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. detailed amino acid and epitope-level immunogenicity “self” scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. read the full case study: [link] about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward looking statements within the meaning of applicable united states and canadian securities laws. forward looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. examples include statements regarding the projected performance, scalability, and market adoption of the company’s lensai™ immunogenicity screening; the ability of its hyft® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ada prediction on biopharma r&d efficiency; and the company’s broader scientific, commercial, and capital markets objectives. forward looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results could differ materially from those expressed or implied because of factors beyond the company’s control, including the pace of scientific and technological innovation in ai driven drug discovery, the accuracy and regulatory acceptance of in-silico ada risk screening, competitive shifts as the industry transitions away from ms dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a bio-native ai company operating at the intersection of techbio and next-generation drug discovery, today announced the appointment of jeff fried to its advisory board. a recognized leader in healthcare data infrastructure and ai innovation, jeff fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. he currently serves as director of platform strategy and innovations for intersystems, where he helps shape high-performance data solutions for some of the world’s most demanding healthcare and life sciences environments. he has served on advisory boards for industry, government, and academia, and served as cto for teloquent (acquired by syntellect), empirix (acquired by infovista), and ba insight (acquired by upland software), as well as product leadership roles at fast search and microsoft. mr. fried has been an enthusiastic advocate for ipa’s lensai™ platform, praising its ability to unify biological sequence, structure, function, and scientific literature into a searchable, ai-ready framework. he has played a pivotal role in supporting biostrand’s partnership with intersystems to integrate advanced vector search capabilities into lensai—helping unlock powerful new possibilities for ai-driven research, diagnostics, and therapeutic development. “we are excited to welcome jeff to our advisory board at a time when our vision for a scalable, bio-native ai infrastructure is rapidly becoming a reality,” said dr. jennifer bath, ceo of ipa. “jeff’s insights at the intersection of healthcare data architecture and ai-enabled discovery are invaluable as we continue to expand lensai’s capabilities and reach across life sciences.” “lensai is one of the most exciting ai platforms i’ve encountered in the life sciences space,” said fried. “it solves a foundational problem—making biological data interoperable and computationally accessible at scale. i’m thrilled to contribute to ipa’s vision and help shape the future of bio-native ai drug discovery.” fried’s appointment underscores ipa’s commitment to enabling discovery work at the speed of computation, not convention, by providing the bio-native ai infrastructure the life sciences industry truly needs—fast, scalable, and grounded in real biological data. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the company’s strategic direction, the company’s future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in ai and biotechnology; and other risks inherent to the company’s industry and business model. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a company operating at the convergence of techbio and biological intelligence, today announced that it has received formal notification from the nasdaq stock market llc (“nasdaq”) confirming that the company has regained compliance with nasdaq listing rule 5550(a)(2), concerning the minimum bid price requirement. the notice, dated july 11, 2025, stated that for the 10 consecutive business days from june 26, 2025, through july 10, 2025, the closing bid price of the company's common shares was at or above $1.00 per share. as a result, immunoprecise has satisfied the requirements for continued listing on the nasdaq capital market, and the matter is now closed. “this compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native ai,” said dr. jennifer bath, ceo of immunoprecise. “we’re building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. the recent momentum in our share price is a strong signal of support for that vision.” through its proprietary lensai™ platform powered by hyft® technology, immunoprecise is reimagining how biological data can be modeled and deployed at scale. the lensai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere. our integrated framework enables unprecedented zero-shot discovery scenarios where lensai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. this unique bio-native ai approach captures functional meaning rather than structural patterns, enabling new capabilities across r&d from drug and vaccine discovery to systems biology and positioning ipa at the frontier of techbio innovation. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the company’s strategic direction, the company’s future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in ai and biotechnology; and other risks inherent to the company’s industry and business model. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

new benchmark confirms lensai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), an ai-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, lensai, powered by ipa’s patented hyft® technology. the newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. “it’s generally assumed that ai can only make accurate predictions if it has seen similar data before,” said dr. jennifer bath, ceo of immunoprecise. “but this benchmark proves otherwise: lensai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. not the antibodies. not the targets. not the complexes. and the predictions aligned with wet-lab results. this is a major breakthrough in generalizing ai for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. it shows that ai doesn’t always need massive data to be powerful and accurate - it just needs the right kind.” lensai epitope mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. unlike traditional methods that take months and require lab work, lensai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. in a new benchmark study, lensai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. despite having no prior exposure to these molecules, lensai achieved prediction scores nearly identical to those from its original training data. this score, known as auc (area under the curve), is a widely accepted measure of accuracy in computational biology. the consistent performance on entirely new, unseen complexes confirms that lensai’s artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. this breakthrough demonstrates lensai’s power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. why this benchmark matters in the new study, lensai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. what it means for partners and investors with lensai already embedded in collaborations across big pharma and biotech, immunoprecise is scaling access through secure apis and custom partnerships. the platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of ai-driven antibody therapeutics. for more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of lensai epitope mapping. the first highlights performance on a “seen” target, where the system was trained on related data. the second - featured in this press release - demonstrates lensai’s breakthrough ability to accurately map binding sites on a completely “unseen” target, with no prior exposure to the antibody, the antigen, or their structure. new case study:lensai epitope mapping on an “unseen” target[ link] previous case study:head-to-head benchmark on a “seen” target[ link] these examples underscore how lensai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the lensai™ and hyft® platforms; the generalizability of the company’s ai models to novel therapeutic targets; the role of ai in accelerating antibody discovery; and the company’s future scientific, commercial, and strategic developments. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for ai-driven therapeutic platforms. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

follow-up to june 5, 2025, announcement demonstrates validated vaccine candidate with strong translational potential austin, texas--(business wire)-- immunoprecise (nasdaq: ipa), a leader in ai-driven biotherapeutics, provides a significant update following its june 5, 2025, press release immunoprecise announces ai-driven breakthrough in universal dengue vaccine discovery. this new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. “this is a major step forward,” said dr. jennifer bath, ceo of immunoprecise. “our ai technology not only found a new target for a universal dengue vaccine, but we’ve now shown it’s safe and can trigger the right immune response. with this validation, we’re excited to move ahead and advance this candidate toward the next stages of vaccine development.” following the recent discovery of a unique “achilles’ heel” shared by all four types of dengue virus, immunoprecise has confirmed—using its patented hyft technology and lensai immunogenicity screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. this breakthrough may pave the way for a safer, more universal dengue vaccine. the new target was discovered using the company’s proprietary lensai platform. “our ability to move from computational discovery to ai-guided immunogenicity validation is unique to our methodology and drug development,” commented dr. jennifer bath, immunoprecise ceo. “further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.” for decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn’t guarantee protection from the others. many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. what makes this development so important is that immunoprecise’s target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both b cells and t cells, in a manner that appears safe and highly specific. immunoprecise’s latest ai-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body’s defenses in a very precise way, without the risks of traditional, broader approaches. a methodology that changes the game—far beyond dengue what sets immunoprecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. with lensai powered by hyft technology, ipa brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. by revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design. the findings for dengue showcase the platform’s versatility. because hyft technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping ipa to tackle a wide spectrum of infectious diseases, from hiv and influenza to emerging pathogens and oncology targets. with this approach, immunoprecise isn’t just keeping pace with the field; it’s setting a new standard for how next-generation therapeutics are discovered and validated. immunoprecise's patented hyft technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (denv-1 through denv-4). this target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine. this hyft-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3d shape. this advanced mapping process combines genetic similarity analysis with 3d structural modeling and functional annotation to identify the most promising vaccine targets. key technical findings complete immune response testing computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (b cells) and infection-fighting cells (t cells) would respond to the vaccine target. the target site showed strong predicted binding to multiple human immune system markers (hla class i and ii types). this suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment. safety verification against human proteins using immunoprecise's proprietary retrieve-and-relate technology at the core of hyft™ ( van hyfte et al., 2023, biorxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. this comprehensive safety check goes beyond standard comparison methods—hyft systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. this is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. no problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells. structural stability analysis advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. stability testing demonstrated that the target remains robust under normal physiological conditions. balanced immune response profile importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. this balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ade)—a serious complication that can worsen dengue infection. looking ahead this release is the second in a series of disclosures aimed at showcasing the power of immunoprecise’s end-to-end ai-native platform. the june 5th announcement introduced a promising target; today’s release provides the crucial next step: a rigorous validation of that target’s safety and immunological relevance. this validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation. these findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. ipa is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the lensai™ and hyft® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of ai-native approaches for dengue and other infectious diseases; and the company’s ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of ai designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

breakthrough in ai-powered drug discovery validates hyft™-driven peptide design, with broad potential across multiple therapeutic areas austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa), a leader in ai-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (ai)-designed glp-1 receptor agonist (glp-1ra) peptide sequences achieve comparable or superior receptor activation to semaglutide, a benchmark glp-1 therapy and one of the most commercially successful drugs in the world. the in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. the results validate the power of ipa’s lensai™ platform and its proprietary hyft™ technology, which enables first-principles-based in silico peptide discovery and optimization. five rationally engineered peptide sequences—ai-optimized for improved stability and peptidase resistance—were tested against benchmark glp-1 analogs in receptor activation assays. two lead candidates outperformed or matched semaglutide under controlled assay conditions. crucially, the sequences were not discovered by chance. they were designed using hyft-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. with glp-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that ai can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same hyft-driven approach. “this is not a one-off success,” said dr. jennifer bath, ceo of immunoprecise. “we’ve demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. hyft-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. it represents a foundational shift in how therapeutics are discovered. the same lensai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with glp-1.” ipa is now considering two complementary preclinical paths for its lead glp-1 candidates: injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. the sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. the significance of this breakthrough extends far beyond glp-1. the same ai framework and hyft-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. this announcement follows ipa’s recent success with ai-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft™ technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the lensai™ and hyft® platforms; the advancement and regulatory acceptance of ai-native drug discovery methods; the continued development and potential preclinical or clinical progression of ipa’s ai-designed glp-1 peptide program; the feasibility of next-generation delivery strategies; and the company’s ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of ai-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

lensai™ powered by hyft® technology identifies a single multi-factorial target conserved across all dengue serotypes. austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary lensai™ platform powered by their patented hyft® technology. this discovery, made using several proprietary hyft-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. this discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the company’s newly launched, hyft pattern-patented ai-native vaccine discovery engine. dr. jennifer bath, immunoprecise antibodies ceo commented, “this breakthrough highlights a new frontier in ai-driven biology—where discovery is rooted in the biology of a virus itself. by confirming that our sequence-derived patented hyft patterns match structural signatures across all dengue serotypes, we’re setting the stage for a universal vaccine design framework. ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. more importantly, the implications appear to stretch far beyond the dengue virus. this is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.” building on this success in dengue, ipa now intends to extend its ai-driven vaccine design platform to other high-impact infectious diseases, for example, hiv, norovirus, and an improved rsv vaccine. early-stage assessments are also underway to explore the platform’s application in oncology for neoantigen vaccine development and tumor-specific epitope mapping. this discovery underscores ipa’s commitment to advancing drug discovery through innovative, human-relevant ai technologies that align with evolving industry standards. using hyft’s patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the company’s proprietary lensai platform identified a unique epitope shared across all four serotypes of the dengue virus—denv-1, denv-2, denv-3, and denv-4. these serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. unlike traditional trial-and-error methods, ipa’s discovery was achieved entirely in silico, demonstrating the platform’s power to translate complex biological data into actionable vaccine design. breaking the dengue barrier: patented hyft-powered ai achieves what decades of science could not why has a universal dengue vaccine been so elusive? dengue is not just one virus—it’s four distinct, rapidly-evolving serotypes. immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. for decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus’s rapid mutation and complex immune interactions. traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale. confirmed breakthrough: sequence and structural hyft match across all four serotypes ipa’s discovery is a landmark moment in computational vaccinology. using its proprietary lensai™ platform powered by their patented hyft® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes—a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. this achievement marks a critical milestone in the quest for a universal dengue vaccine. what sets this apart is the depth of validation: · patented hyft patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural hyfts across all four dengue serotypes. · this was made possible through lensai’s integration of over 20 million proprietary structural hyfts (s-hyfts), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints. · the validation demonstrates that lensai doesn’t simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-em. this milestone affirms the patented hyft technology’s unique ability to traverse the full biological hierarchy—from dna/rna sequence to molecular structure to therapeutic relevance. it signals that ai-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research. the end-to-end lensai platform integrates patented hyft® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. the result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. these statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the lensai™ and hyft® platforms; the advancement and regulatory acceptance of ai-native drug discovery and vaccine development methods; the expansion of ipa’s discovery engine to additional infectious disease and oncology targets; and the company’s ongoing ability to maintain scientific, regulatory, and commercial momentum. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the lensai™ platform, with a direct comparison to gold-standard wet-lab methods. the results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. lensai’s ai-powered platform was able to match the performance of x-ray crystallography—the industry’s most precise but slowest and most expensive method—using sequence data alone. "in an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn’t a luxury—it’s a necessity," said dr. jennifer bath, ceo of ipa. "with lensai, we’re demonstrating that ai is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work." in the benchmarking study, lensai’s in silico epitope mapping application was tested across five known antibody-antigen pairs and against multiple experimental techniques, including hdx-ms, alanine scanning, and x-ray crystallography. the ai system produced predictive scores (auc 0.79–0.89) comparable to or exceeding those achieved by leading wet-lab methods, while reducing turnaround time from weeks to hours. epitope mapping is a cornerstone of antibody development, informing everything from ip strategy to candidate selection. traditionally, this requires expensive, time-consuming lab work using scarce protein samples. lensai transforms this by delivering early-stage epitope insights from sequence alone, reducing both cost and risk. this breakthrough aligns with growing regulatory and industry momentum around new approach methodologies (nams), including the fda’s recent decision to phase out animal testing requirements for biologics. by eliminating the need for physical materials and enabling near–x-ray-level precision, lensai advances ethical, scalable, and high-resolution approaches to biotherapeutic discovery we view this achievement as a meaningful advancement that enhances the capabilities of drug discovery platforms" added dr. bath. "lensai is now capable of providing pharma and biotech partners with validated, in silico answers to questions that once required months of wet-lab commitment." this latest achievement marks a major step in the broader development of lensai, ipa’s ai-driven discovery platform. building on previous releases, including in silico antibody engineering, epitope prediction, and multi-omics integration, lensai continues to demonstrate its ability to deliver high-resolution, scalable insights across key stages of biotherapeutic discovery. today’s advancement in epitope mapping reflects the growing power of the platform we have been strategically building — connecting sequence-based precision, accelerated timelines, and deep scientific insight to transform the future of therapeutic development. to read the full case study: lensai epitope mapping matches x-ray crystallography about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as "expects," "intends," "anticipates," "believes," or variations thereof, or state that certain actions, events, or results "may," "will," "could," or "might" occur. these statements relate to, among other things, the anticipated benefits, scalability, and adoption of the lensai platform, the broader application of hyft®-based tools, the advancement of ai-native drug discovery methods, and the company’s ability to maintain regulatory alignment and commercial traction. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory changes and acceptance, competitive dynamics, ip protection, platform integration challenges, and financial and operational risks. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) a leader in ai-driven biotherapeutics, today announced its strong support for the u.s. food and drug administration’s (fda) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. the fda’s announcement marks a significant advancement in regulatory modernization and aligns fully with immunoprecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary ai platform, lensai™. “this policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,” said dr. jennifer bath, ceo of immunoprecise antibodies. “ipa has long championed the transition toward more ethical, efficient, and accurate methodologies. our ai-powered lensai™ platform and suite of integrated discovery tools were designed precisely to support this new era of translational science.” ipa provides validated ai-driven methodologies that directly align with the fda's shift towards new approach methodologies (nams). these advanced tools effectively address critical drug development challenges, including safety, toxicity, immunogenicity, and efficacy, by leveraging sophisticated predictive capabilities: 1. safety and toxicity prediction: ipa’s lensai platform utilizes ai analytics to accurately predict potential toxicities by mapping drug interactions across the human proteome, significantly reducing the reliance on animal models. 2. immunogenicity screening: the platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient-specific strategies. 3. knowledge graphs for drug efficacy: ipa’s semantic knowledge graphs integrate biological data and scientific literature, enabling precise predictions of drug efficacy and interactions in human systems. through transitioning from animal testing to ai-driven methodologies, ipa aims to streamline preclinical workflows, reduce development costs, uphold higher ethical standards, and support regulatory compliance in line with the fda’s nams framework. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of ipa’s ai-driven methodologies, the integration of lensai and biostrand’s platforms into drug discovery, and the potential impact of regulatory shifts on ipa’s business and product development. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

programs to be driven through patented ai technology and advanced proprietary b cell platforms partnership advances next-generation adcs and bispecific antibodies to address unmet medical needs austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of antibody-drug conjugates (adcs) and bispecific antibodies for the treatment of cancer. this collaboration focuses on leveraging contract research expertise while integrating ipa’s proprietary b-cell select™ platform and artificial intelligence-driven discovery capabilities to enhance the efficiency and precision of therapeutic development. under the terms of the agreement, the partnership will encompass the discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, with a focus on developing highly selective and effective cancer treatments. ipa’s proprietary multi-omics ai-driven modeling and discovery platform, combined with its b-cell select™ technology, will be integrated at key stages to optimize therapeutic selection and accelerate lead development. the agreement, valued at an initial $8 million with the potential to expand to $10 million based on program progression, will span 18 to 24 months, integrating artificial intelligence across the workflow to enhance discovery and optimization. this collaboration aims to streamline the path from target discovery to preclinical candidate selection, marking a significant step toward advancing next-generation biologics for cancer treatment. “this partnership underscores the power of combining ai-driven discovery with advanced antibody engineering,” said dr. jennifer bath, ceo of immunoprecise antibodies. “with the purchase order secured and work already underway, we are actively leveraging our proprietary b-cell select™ platform and lensai™ technology to accelerate the development of highly targeted cancer therapeutics. this collaboration highlights ipa’s role in shaping the future of next-generation biologics with data-driven precision and efficiency.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of the collaboration, the integration of ai-driven workflows into drug discovery, and the potential impact of the partnership on advancing adc and bispecific antibody development. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a global leader in ai-powered antibody discovery and development, today announced a strategic collaboration with ribopro, a pioneering technology provider specializing in mrna and lipid nanoparticle (lnp) technologies. this collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating ribopro’s advanced mrna-based antigen expression expertise with ipa’s in silico and wet-lab antibody discovery capabilities. the collaboration leverages ribopro’s expertise in mrna sequence optimization and lnp-based delivery with ipa’s advanced b-cell screening, single-cell analysis, and deep-learning ai-driven discovery workflows. together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery. transforming antibody discovery with mrna technology the success of generating therapeutic lead antibodies towards complex antigens using traditional immunization-based discovery platforms may be hampered by challenges associated with the proper expression of these antigens. by leveraging ribopro’s proprietary mrna and lnp technologies, this partnership enables precise, efficient antigen expression, thereby facilitating potentially more effective immune responses and possibly accelerating the path to discovering novel antibody therapeutics. “partnering with immunoprecise antibodies enables us to push the boundaries of mrna-based immunization for therapeutic antibody discovery,” said sander van asbeck, ceo of ribopro. “by integrating our expertise in mrna design and nanoparticle delivery with ipa’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen expression, bringing forth new possibilities for precision therapeutics.” driving innovation in ai-powered antibody discovery ipa’s approach combines advanced ai-driven analytics with highly specialized wet-lab methodologies to design and optimize antibodies with the highest clinical relevance. the integration of mrna immunization into ipa’s workflow is expected to further enhance the precision and efficiency of their antibody discovery pipeline. “we are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mrna immunization platform in this alliance,” said dr. ilse roodink, cso of immunoprecise antibodies. “combining ribopro’s and ipa’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.” about ribopro ribopro is a netherlands-based technology and service provider specializing in mrna and lipid nanoparticle (lnp) technologies. founded in 2020, ribopro develops and manufactures high-quality mrna and lnps while offering innovative solutions, including sequence optimization algorithms and a proprietary lnp platform. these technologies are designed to enhance immune responses, improve safety profiles, and enable targeted mrna delivery beyond the liver. ribopro provides cmo, cdmo, and cro services to biotech and pharmaceutical companies seeking next-generation solutions for mrna therapeutics. for more information, visit www.ribopro.eu media contact: silvy van tuijl, chief of staff, ribopro | info@ribopro.eu |+31 85 060 67 62 about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutic research and technology company specializing in ai-driven antibody discovery and development. through its subsidiaries—including talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v.—ipa delivers an end-to-end solution for the development of next-generation antibody therapeutics. the company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets. for more information, visit www.ipatherapeutics.com investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the collaboration between immunoprecise antibodies ltd. (“ipa”) and ribopro, the potential for mrna-based antigen expression to enhance antibody discovery and development, and the ability of the partnership to accelerate the creation of novel immunotherapies. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024, (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas--(business wire)-- immunoprecise antibodies (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of kamil isaev to its board of directors and joseph scheffler as interim chief financial officer (cfo). additionally, ipa announces the planned departure of chris buyse from the board of directors. kamil isaev joins ipa’s board of directors ipa is pleased to welcome dr. isaev, a seasoned technology leader and venture strategist, to its board of directors. with over 30 years of expertise in ai, semiconductor technologies, and global r&d operations, isaev has held leadership roles at intel, dell emc, align technology, and abrt vc. his career has been defined by scaling r&d centers, driving ai-driven innovation, and leading high-impact cross-functional teams to bring emerging technologies to market. isaev currently serves as a venture partner at abrt vc, where he leads the abrt ai lab and the vc score project, developing ai-powered evaluation models to assess and rank ai startups, providing investors with data-driven insights to identify high-potential opportunities. his role at abrt vc is focused on bridging cutting-edge ai research with commercialization strategies, helping ai-driven companies refine their go-to-market approach and maximize scalability. previously, he held key leadership positions at intel corporation, where he served as director of developer relations engineering, overseeing global ai and software development teams and spearheading ai computing optimization, gpu workload migration, and machine learning integration. in this role, he worked closely with intel’s partners and customers to drive adoption and deployment of ai technologies in commercial and enterprise applications. before that, as country r&d general manager, he managed various software initiatives, ensuring efficient deployment of machine learning and deep learning solutions across intel's ecosystem, with a focus on operational efficiency and real-world implementation. beyond intel, isaev has led r&d and technology commercialization efforts at various organizations. at align technology, he managed a 600+ engineer r&d division, driving enterprise-wide digital transformation and agile adoption, while ensuring the successful transition of research initiatives into commercially viable products. as vice president of operations at caresyntax, he played a key role in the company’s u.s. expansion and the development of ai-driven surgical intelligence solutions, ensuring the integration of ai-driven insights into clinical workflows. at dell emc, he led solutions architecture for ai, healthcare, and video surveillance, focusing on bridging advanced technology development with industry adoption. isaev is also a member of ieee, a guest lecturer at leading universities, and a frequent speaker at ai and semiconductor industry conferences. he holds an msc and phd in physics (plasma physics and plasma chemistry) from moscow state university and has authored over 30 scientific publications in plasma physics and semiconductor technology. “we are delighted to welcome dr. isaev to our board,” said dr. jennifer bath, president and ceo. “his deep expertise in ai, r&d leadership, and commercialization of cutting-edge technology will be invaluable as we continue to expand our ai-driven biologics platform. kamil's proven track record in developing go-to-market strategies and his experience in bringing emerging technologies to commercial success aligns perfectly with our mission. his insights will be crucial as we navigate the complex landscape of ai in biologics and accelerate our path from innovation to market impact.” joseph scheffler appointed interim cfo ipa also announces the appointment of joseph scheffler as interim chief financial officer. scheffler is a highly experienced finance professional with over 20 years in public and multinational companies, specializing in financial reporting, forecasting, and business strategy. most recently, as interim corporate controller at nidec - kinetek, scheffler managed consolidated financial reporting for a $400 million global manufacturing firm with 40 subsidiaries worldwide. his background also includes extensive financial consulting for acquisitions and corporate strategy development, making him well-equipped to oversee ipa’s financial operations. “joseph brings a wealth of financial expertise and strategic insight,” said dr. jennifer bath. “his leadership will be instrumental in strengthening our financial strategy and supporting ipa’s continued growth.” scheffler holds an mba in finance and a bachelor’s in accounting from loyola university chicago, combining analytical expertise with strong stakeholder engagement. chris buyse departs board of directors ipa also announces that chris buyse has stepped down from the board of directors following his valuable tenure supporting the company during a transitional phase. “we are grateful to chris for his contributions and financial stewardship during this period of strategic evolution,” said dr. bath. “his expertise has been instrumental in ensuring continuity as we positioned the company for its next phase of growth. we wish him all the best in his future endeavors.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutic research and technology company specializing in ai-driven antibody discovery and development. through its subsidiaries—including talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v.—ipa delivers an end-to-end solution for the development of next-generation antibody therapeutics. the company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets. for more information, visit www.ipatherapeutics.com investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated contributions of kamil isaev as a member of the board of directors, the expected impact of joseph scheffler’s appointment as interim cfo, and the company’s continued strategic growth and execution of its ai-driven biologics initiatives. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to leadership transitions, technological advancements, regulatory developments, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should any of these risks materialize actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

biostrand completes integration of 20 million proprietary structural hyfts™ used as a navigational layer to parse over the protein predictive platforms alphafold-2 and evolutionary scale modeling (esm)-2 fold hyfts are now linked together by more than 25 billion relationships within the knowledge graph (kg) biostrand announces artificial intelligence collaboration and license agreement to discover and develop anti-cancer antibodies with briacell therapeutics ipa antibodies announced voluntary delisting from tsx venture exchange niaid confirms ipa’s polytope tatx-03 neutralizing activity against the currently spreading sars-cov-2 variant ba.2.75 victoria, british columbia (canada), december 15, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal year 2023, which ended october 31, 2022. “our focus on accelerated revenue development and the sales integration of our in silico capabilities using innovative and unique hyft-based technology was continued in the second quarter. with relevant outputs and advancements in drug discovery, ipa has quickly pushed the frontiers of cutting-edge innovation, building upon our already top-ranked global cro,” stated dr. jennifer bath, ceo of ipa. “along with continued corporate growth, we remain intently focused on maximizing shareholder value and we continue to swim against the tide of the downward market trend. however, we are not content. we have immense objectives, and we’re determined to work nonstop until we achieve them.” second quarter fiscal year 2023 financial summary* (all comparisons are to the period ended october 31, 2021) ipa achieved revenue of $5.2 million during the three months ended october 31, 2022, an increase of 9.8% compared to the three months ended october 31, 2021. during the three months ended october 31, 2022, research and development expense increased to $4.6 million from $3.0 million during the three months ended october 31, 2021. the increase in research and development costs is primarily attributable to spend associated with clinical manufacturing of the company’s polytope® antibody combination therapy. as of october 31, 2022, ipa held cash of $15.1 million. *expressed in canadian dollars, unless otherwise indicated. financial results revenue ipa achieved revenue of $5.2 million during the three months ended october 31, 2022, a 9.8% increase from the three months ended october 31, 2021. growth was primarily driven by increases in protein manufacturing and ipa’s b cell select® platform. research & development during the three months ended october 31, 2022, research and development expenses increased to $4.6 million, from $3.0 million during the three months ended october 31, 2021. the increase in research and development costs is primarily attributable to spend associated with clinical manufacturing of ipa’s polytope® antibody combination therapy. additional research and development expenses included salaries and benefits (including share-based compensation) of $0.3 million, and depreciation expense of $0.1 million. liquidity and capital resources as of october 31, 2022, ipa held cash of $15.1 million as compared to $30.0 million as of april 30, 2022, and had working capital of $15.4 million. conference call: date: thursday, december 15, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/662019205 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the speed and commercialization of discovery processes and integration of in silico models. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above mentioned hyfts and the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release.

structural hyft technology is used as a navigational layer to parse over the protein predictive platforms alphafold-2 and evolutionary scale modeling (esm)-2 fold hyft technology explores formal and explicit biologically relevant knowledge and connects information about sequence, structure, and function hyft technology is continuously enriched, e.g., by the structural models released by esm-2 fold and alphafold-2 hyfts are now linked together by more than 25 billion relationships within the knowledge graph (kg) victoria, british columbia (canada), december 8, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, today announced that its subsidiary, biostrand bv, has completed the full integration of 20 million structural hyfts with deepmind’s alphafold and meta’s esm-2 fold platforms. protein wars: alphafold-2 vs esm-2 fold recent efforts to predict the three-dimensional structure of a protein using ai are progressing as a solution to the protein folding challenge. a protein’s three-dimensional structure can be studied with the same level of accuracy as experimental methods, thanks to alphafold, a protein structure analysis ai created by deepmind, an alphabet business focused on artificial intelligence. in july 2021, alphafold became publicly available and is credited with revolutionizing biology. a searchable database containing the three-dimensional structures of more than 200 million proteins predicted by alphafold was released in july 2022. the esm metagenomic atlas, a database that predicted the structure of over 617 million metagenomic proteins, was then presented in november 2022 by meta ai, a facebook research team focused on generating knowledge for the ai community. the study of genomes that have been retrieved directly from environmental samples is known as metagenomics. esm is a ground-breaking approach developed by meta ai researchers to predict protein structure. this model is one of the closest alternatives to deepmind’s alphafold-2, which reportedly resolved the 50-year-old grand challenge of in silico protein folding. meta ai has introduced several models throughout the years, and the public can now see its most recent efforts. esm-2 fold inference is quicker at enabling the investigation of structural spaces of metagenomic proteins, even though alphafold-2 and rosettafold have higher accuracy. numerous protein structure prediction models exist in addition to esm-2 fold and alphafold-2, such as rosettafold, omegafold, intfold, raptorx, and others. the esm fold model from meta’s protein structure prediction ai translates the atoms and molecules that make up the protein into language and predicts the three-dimensional structure from the learning data. the group developed the esm-2 with 15 billion parameters by extending this model. esm-2, the largest protein language model to date, employs 2,000 gpus, and is able to predict the three-dimensional structure of more than 600 million proteins in the esm metagenomic atlas in just two weeks. meta ai’s research team claims that while esm-2’s structure prediction speed is up to 60 times faster than alphafold’s, its prediction accuracy is inferior to that of alphafold. this suggests that structure prediction can be scaled to considerably larger databases, according to meta. the hyft technology hyfts are universal fingerprinttm patterns mined throughout the whole biosphere. when linked together, they form a knowledge graph that constitutes over 660 million hyfts and more than 25 billion relations. the core characteristic is that these hyfts can connect sequence to structure and function, but also link sequence to all types of textual information such as scientific papers and medical records. recently, the company also added more than 20 million structural hyfts (s_hyfts) to this graph, and continuously adds metadata and relations. this strengthened the hyft-based platforms with the double compounded effect of harnessing the structural prediction capabilities of alphafold-2 and esm-2 as navigational layers for the hyfts to parse over, while integrating the associated knowledge and speeding up the discovery processes. continuously enriching and updating the hyft graph with the latest novelties is a core characteristic. this means that the number of relationships within the graph is exponentially growing. it provides the hyft-based lensai platforms with constantly updated and integrated knowledge relevant within a biological context. what makes this graph unique is the wealth of explicit information on the whole biosphere that is represented. since graphs hinge on relationships, they allow one to easily and efficiently determine and visualize the connectedness of different entities in this biosphere. furthermore, it equips the lensai platform with an extremely powerful starting point for further application of various ai and machine learning techniques in antibody discovery and precision medicine. the hyft graph provides a unique intermediate layer between sequences and predictions, allowing new knowledge and insights to be extracted without having the downside of operating in a black box. from knowledge graph to undiscovered knowledge why does it matter to have a huge knowledge graph covering the whole biosphere? the richness of a graph determines the depth and level of detail of new information and knowledge that can be extracted. having access to a wealth of 25 billion relationships empowers fine-grained levels of exploration that were not possible before. it opens a whole new world of undiscovered knowledge. in addition to the magnitude of relations, the biological relevance of the information is key. here, the hyft knowledge graph’s unique ability to connect sequence, structure, function, and literature is unprecedented. in silico and wet lab integrated biostrand’s ai-driven approach and ipa’s best-in-class laboratory capabilities are leveraging our target-agnostic antibody discovery platform to create the best possible drugs in a variety of therapeutic domains. supporting the wet lab with the most up-to-date and complete information and predictions using a wide range of in silico models accelerates wet-lab experiments, and generally makes them more efficient and insightful. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the effect of the integration of 20 million structural hyfts to the knowledge graph on structural prediction capabilities and speed of the discovery processes, as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above mentioned hyfts and the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, vancouver, british columbia (canada), and philadelphia, pa, november 30, 2022 – ipa (immunoprecise antibodies ltd.) ( “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, today announced that biostrand bv (“biostrand”), an ai in silico discovery subsidiary of ipa, has entered into a research collaboration and license agreement (the “agreement”) with briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. the collaboration will leverage biostrand’s lensai™ software, built upon ipa’s proprietary hyft™ universal fingerprint™ technologies, and will focus on in silico antibody discovery to generate relevant clinical molecules for potential development. under the terms of the agreement, biostrand and briacell will collaborate on the design, discovery, and development of anti-cancer antibodies. upon successful antibody discovery, biostrand will receive an upfront payment of us$500,000, and will be eligible to receive future success-based development milestones, including those for the submission of investigational new drugs (inds), clinical milestone payments, and commercial royalties on net sales of products. further terms are not disclosed. “we are very excited to begin this program with briacell and apply our technology to the development of biologics that may have a huge clinical impact,” stated dr. ingrid brands, general manager and co-founder of biostrand. “shortening timelines, while also integrating as much information as possible upstream to improve the efficiency of the process, is extremely important in the development of highly targeted therapies. it is a step towards realizing our long-term vision of significantly advancing precision medicine.” “we believe that biostrand’s revolutionary ai-powered technology, combined with its cutting-edge protein engineering platform, will allow us to design and discover potent anti-cancer therapeutics,” stated miguel a. lopez-lago, phd, chief scientific officer of briacell. “this approach would complement briacell’s current immunotherapy pipeline of innovative anti-cancer therapeutics.” about briacell therapeutics corp. briacell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. more information is available at www. briacell.com immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements relating to the anticipated impact and results of ipa’s collaboration with briacell as well as statements relating to the amount and timing of payments and commercial royalties to be received by briacell. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the results of ipa’s collaboration with briacell may not be as benefical as expected, milestones leading to payments from briacell may not all be met or at all, the amount of global net sales leading to commercial royalties may be less than expected; as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. contact information contact (immunoprecise antibodies ltd.): investor contact: investors@ipatherapeutics.com contact (briacell therapeutics corp.) : william v. williams, md president & ceo 1-888-485-6340 info@briacell.com media relations: jules abraham director of public relations core ir 917-885-7378 julesa@coreir.com investor relations contact: core ir investors@briacell.com source immunoprecise antibodies

victoria, british columbia (canada), november 22, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) announces that it has applied and has received approval for a voluntary delisting of its common shares from the tsx venture exchange (“tsxv”). accordingly, it is anticipated that, effective as at the close of trading on friday, november 25, 2022, ipa’s common shares will no longer be listed and posted for trading on the tsxv. the delisting from the tsxv will not affect the company’s listing on the nasdaq global market (the “nasdaq”). the common shares will continue to trade on the nasdaq under the symbol “ipa”. the company believes that the trading volume of its shares on the tsxv no longer justifies the expenses and administrative efforts required to maintain a dual listing. the company also believes that delisting from the tsxv will create a central marketplace for its common shares on the nasdaq, and ultimately benefit the long-term liquidity and shareholder value of the company. following delisting from the tsxv, ipa’s shareholders can trade their common shares through their brokers on nasdaq. as most brokers in canada, including many discount and online brokers, have the ability to buy and sell securities listed on nasdaq, ipa’s nasdaq listing will continue to provide shareholders with the same accessibility to trade the company’s common shares. shareholders holding shares in canadian brokerage accounts should contact their brokers to confirm how to trade ipa’s shares on the nasdaq. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements with respect to the timing of the delisting of the common shares from the tsxv, the anticipated benefits of delisting from the tsxv as well as future results, the accessibility of and ability to trade the company’s common shares on the nasdaq, and the anticipated continued listing of the company’s common shares on the nasdaq. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, regulatory filings may not be filed or approved on a timely basis, or at all; ipa’s common shares may not be delisted from the tsxv on the expected date or at all; trading the company’s common shares on the nasdaq may not be as accessible as expected; as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. contacts investor contact: investors@ipatherapeutics.com

under strategic collaboration, talem, an ipa subsidiary, expands its relationship with ligand/omniab, inc., to develop three immuno-oncology programs targeting validated targets talem intends to leverage ipa’s broad range of advanced laboratory and in silico computational technologies, including lensai™ antibodies were discovered using omnichicken antibody discovery technology victoria, british columbia (canada), october 12, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), today announced that its subsidiary, talem therapeutics llc (“talem”), has entered into a multi-target license agreement with omniab, inc., a subsidiary of ligand pharmaceuticals incorporated. the agreement builds upon talem’s extensive antibody development expertise and its access to lensai™ in silico software technology to further the development and commercialization of omnichicken-derived antibody panels against b7h3, cd38 and tim3, which are immuno-oncology targets. the collaboration leverages antibodies from the omnichicken discovery technology, the industry’s first successfully engineered bird with an immune system that can efficiently generate human sequence antibody repertoires for the discovery of therapeutic antibodies, with talem’s advanced antibody development technologies aimed at optimizing clinical success. under the terms of the agreement, talem will oversee the development and optimization of the antibodies for each program. omniab and talem will share downstream economics upon potential out-licensing or commercialization of the programs. “this collaboration leverages talem’s unique strengths in optimizing and developing scientifically rigorous and clinically-relevant antibodies and provides an exceptional opportunity to apply ai-driven in silico technologies available to talem to rapidly develop antibodies derived from the omnichicken discovery technology,” stated dr. jennifer bath, ceo of ipa. dr. bath continued, “we believe that the expertise of the ipa family with a variety of antibody formats and broad range of powerful in silico and advanced wet lab technologies, will enable talem to meaningfully accelerate the development of these potential life-saving therapies faster and with more accuracy than ever before.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the anticipated developments resulting from the collaboration between talem and crystal. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in developing commercially viable products from the antibodies licensed from ligand pharmaceuticals’ subsidiary, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

victoria, british columbia (canada), september 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), announced today that its subsidiary, talem therapeutics llc (“talem”), has shared positive results of a new study conducted by the national institute of allergy and infectious disease (niaid), part of the national institutes of health (nih), that has shown the continued resilience of polytope® tatx-03 in broadly neutralizing sars-co-v-2 variants, including two omicron sublineages that had not been previously tested. this niaid-conducted pseudovirus-based study has reconfirmed the neutralizing activity of tatx-03 against the european variant (d614g mutant) of the parental virus and several previously tested variants, including delta (b.1.617.2), and omicron sublineages (ba.2, ba.4/5). importantly, tatx-03 has now demonstrated its neutralizing activity against the currently spreading ba.2.75 variant. maintained neutralizing potency was also confirmed for the omicron sublineage ba.2.12.1, sars-co-v-2 variant that had not yet been screened in virus neutralization studies. ipa’s chief scientific officer (cso), dr. ilse roodink, stated: “we appreciate that our interactions with the fda resulted in this collaboration with the niaid. this division of the nih is continuously screening clinical-stage antibody therapeutics for neutralizing potency towards emerging variants. we highly value this independent validation of the resilience of our polytope® tatx-03 product, further strengthening our position as we progress into clinical trials in humans.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic research and technology company that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to successfully submit a clinical use application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely submission of an application for regulatory approval, developing its polytope® tatx-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of polytope® tatx-03, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

structural hyfts fully indexed and integrated in structure-function workflow lensai® data management platform successfully launches hyper-scalable solution for partner access, integrating multiple data layers at once company shares biostrand case study demonstrating the complete in silico prediction of off-target effects from a top 10 pharma late-stage clinical antibody ipa successfully demonstrates t-cell engager strategy with tatx-112 bi-specific antibody tatx-22 program focus on the development of a novel, best-in-class bi-specific antibodies for acute myeloid leukemia ipa announces completion of in silico case studies as first sign of ability to address key antibody technologies without the use of wet lab assistance, results currently under in vitro company announces validation from niaid on polytope tatx-03 combination therapy neutralization of several variants, including the currently spreading subvariant, ba.2.75. victoria, british columbia (canada), september 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended july 31, 2022. “our biggest surprise this quarter was how rapidly our iterative-feedback ai software platform for antibody discovery advanced toward commercialization,” stated dr. jennifer bath, ipa’s chief executive officer. “we are clearly excited about the potential of our most recent acquisition, biostrand, and look forward to working together to leverage their elegant software and iterative ai platform with ipa’s clinically validated wet lab technologies, to realize the full potential of our capabilities to deliver the next generation of cancer and immunology therapies to modernize all aspects of antibody discovery and development,” dr. bath continued, “we aim to transform how we discover and develop novel therapeutics as we continue to shorten drug discovery timelines and to design safer, more targeted therapies for patients.” first quarter fiscal year 2023 financial summary* (all comparisons are to the period ended july 31, 2021) the company’s total revenue of $4.7 million was an increase of $0.1 million or 2.2% as compared to total revenue of $4.6 million from the same period last year. the company, primarily through its subsidiary talem therapeutics llc, invested $5.8 million in strategic research and development costs as compared to an investment of $1.1 million in the same period last year. the company recorded a net loss of $9.4 million, as compared to net loss of $3.2 million during the same period last year. as of july 31, 2022, the company held cash of $19.2 million. *expressed in canadian dollars, unless otherwise indicated. financial results revenue the company achieved revenue of $4.7 million during the three months ended july 31, 2022, a 2.2% increase from the three months ended july 31, 2021. growth was primarily driven by increases in protein manufacturing and cryostorage services. revenue during the three months ended july 31, 2022, was impacted by the weakening of the euro due to the effect of foreign currency translations. on a consolidated basis, total revenue was negatively impacted by $0.3 million as compared to the three months ended july 31, 2021. research & development r&d increased to $5.8 million from $1.1 million during the three months ended july 31, 2021, primarily due to strategic investment in the company’s sars-cov-2 polytope® antibody combination therapy. a total of $5.2 million in costs were incurred for gmp manufacturing of the therapy. net loss the company recorded a net loss of $9.4 million during the three months ended july 31, 2022, compared to a net loss of $3.2 million for the three months ended july 31, 2021. the increased net loss is primarily due to the company’s investment in r&d related to the sars cov-2 polytope® cocktail, increased salaries and benefits to support the company’s strategic plans, increased amortization from intangible assets recorded in connection with the biostrand acquisition, and increased consulting fees. liquidity and capital resources as of july 31, 2022, the company held cash of $19.2 million as compared to $30.0 million as of april 30, 2022, and had working capital of $21.7 million. the company’s internal forecast indicates the cash on hand will sustain its existing operations for at least 12 months. on october 13, 2021, an at-the-market (“atm”) equity offering facility was entered into with h.c. wainwright & co., llc as sole sales agent (“agent”). the company will be entitled, at its discretion and from time-to-time during the term of the atm agreement, to sell through the agent common shares of the company having an aggregate gross sales price of up to us $50 million. as of september 14, 2022, us $50 million of the company’s stock remained available for sale under the atm facility. conference call: date: wednesday, september 14, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/349012238 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company’s periodic reports on file with the toronto stock exchange and securities and exchange commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic research and technology company that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of ipa’s polytope monoclonal antibodies, including tatx-03, to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment, to retain efficacy over time, and to reduce or suppress the emergence of novel variants as well as its potential to prevent the spread of variants. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in developing its polytope monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. *non-ifrs financial measure readers are cautioned that “adjusted ebitda” is a measure not recognized under ifrs. adjusted ebitda is defined as operating earnings before interest, accretion, taxes, depreciation, amortization, share-based compensation, foreign exchange gain/loss, and asset impairment charges. management believes adjusted ebitda is a useful measure that facilitates period-to-period operating comparisons. readers are cautioned that “adjusted ebitda” is not an alternative to measures determined in accordance with ifrs and should not, on its own, be construed as indicator of performance, cash flow or profitability. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release.

victoria, british columbia (canada), august 29, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), a biotherapeutic research and technology company, today announced the continuing success of polytope® tatx-03 antibody combination therapy to neutralize variants of concern of the covid-19 causative virus, including the latest omicron ba.5 subvariant, validated by an independent research organization in an authentic virus assay. research was conducted by the max von pettenkofer institute, part of the medical faculty of the ludwig-maximilians-university (lmu, munich, germany), who is world-renowned for their research and diagnostic services on sars-cov-2. the blinded studies examined the efficacy of ipa’s polytope® tatx-03 antibody combination therapy alongside in-house derived formulations of several commercially approved antibodies. authentic isolates of virus variants tested in vitro by the lmu institute included 20e (eu1; b.1.177), alpha (b1.1.7), beta (b.1.351), delta (b.1.617.2), omicron lineages ba.1 (b.1.1.529.1), ba.1.1 (b.1.1.529.1.1), ba.2 (b.1.1.529.2), and ba.5 (b.1.1.529.5). whereas commercially licensed products had difficulty to protect the susceptible cells against some of the listed coronavirus (sub)variants, ipa’s polytope® tatx-03 was able to neutralize all (sub)variants tested, including the currently dominant omicron ba.5 subvariant, which has been described to display increased immune evasion compared to ba.1, ba.2 and pre-omicron variants. as the spike trimer of the ba.4 omicron variant is identical to ba.5 glycoprotein, the company anticipates that the consistent neutralizing potency of tatx-03 hold true for this variant. ipa’s chief scientific officer (cso), dr. ilse roodink, stated: “while underway to the first clinical trials of our polytope® in humans, this independent confirmation of the strength of our rationally designed combination therapy using authentic virus variants is very valuable for our ongoing discussion with the authorities. with the rapid evolution of omicron and its variants, the need for a sustainable therapy to sars-cov-2 infection becomes increasingly evident”. she continued, “while our first-generation tatx-03 therapy has proven its resilience in vitro, we are confident about the anticipated in vivo efficacy in humans, as some components of our cocktail are able to mediate anti-viral effects through mechanisms which may enhance the already proven performance in the prior in vitro neutralization assays.”. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic research and technology company that leverages network biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to successfully submit a clinical use application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely submission of an application for regulatory approval, developing its polytope® tatx-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of polytope® tatx-03, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f,dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

the company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021 the company achieved record revenues of $5.2 million for the three months ended april 30, 2022, an increase of 7.4% over the same period last year. the company achieved an increase in cro revenue (total revenue minus talem asset out-licensing revenue) of 15.9% over the same period last year. victoria, british columbia (canada), july 29, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended april 30, 2022. fiscal 2022 financial summary* the company achieved record total revenues of $19.4 million during the year ended april 30, 2022, an 8.1% increase from the year ended april 30, 2021. project revenue of $17.4 million was $1.4 million, or 9.1%, higher than last year. growth is driven primarily by the company’s b cell select® platform, with expansion in both the number and size of projects under contract. the company, primarily through its subsidiary talem therapeutics llc, invested $6.7 million in strategic research and development costs as compared to $2.0 million in 2021. the company recorded a net loss of $16.7 million during the year ended april 30, 2022, compared to a net loss of $7.3 million for the year ended april 30, 2021. as of april 30, 2022, the company held cash of $30 million (april 30, 2021 – $41.8 million) *expressed in canadian dollars unless otherwise noted. “we delivered another year of strong performance in fiscal year 2022, demonstrating both our highest revenue quarter and fiscal year in the history of ipa,” said dr. jennifer l. bath, chief executive officer, ipa. “we are entering fiscal year 2023 with significant momentum and a strong focus and expectations on our new capabilities, robust pipeline, and excellent execution to deliver continued strong performance this year and over the long-term.” recent and fiscal 2022 operational highlights ipa seeks to rapidly and dramatically expand its ip portfolio with the addition of several us and international patent applications submitted by talem therapeutics llc and obtained through the recent biostrand acquisition ipa announces the retirement of lisa helbling, chief financial officer, and the appointment of her successor and current member of the ipa executive team, brad mcconn, effective august 5th. pre-clinical, ind-enabling histopathology data from toxicity study and ex vivo human tissue cross-reactivity (tcr) analysis support the safety of ipa’s polytope® tatx-03 cocktail ipa’s polytope® tatx-03 demonstrates protection against in vitro infection by omicron sublineage ba.2, in addition to all other variants of concern ipa completes acquisition of belgian group, biostrand, revolutionizing biotherapeutics with method to encode omics and power drug development with advanced artificial intelligence (ai) ipa’s newly acquired subsidiary, biostrand, awarded second round of grant funding from vlaio research grant ipa and chempartner biologics announce polytope® tatx-03 antibody cocktail manufacturing collaboration after program review by the department of defense (dod), ipa was selected to work with elektrofi on a deployment ready formulation of its polytope tatx-03 as well as future pandemic preparation under an sbir contract from defense health agency (dha) within the us dod ipa bolstered global senior leadership with barry duplantis, ph.d., promoted to vice president of client relations and the addition of ms. carla dahl, vice president of marketing ipa europe granted three-year approval for the “crédit d’impôt recherche” (cir) from the french ministry of higher education and research to provide research tax credits to eligible french companies the company established a multi-target research collaboration with pierre fabre in immuno-oncology ipa established a us $50 million at-the-market distribution agreement (the “atm”) ipa presented in vitro characterizations results from studies on tatx-21, a novel potential first-in-class antibody for atherosclerosis cardiovascular disease (acvd), at the 2021 bio convention ipa enters co-offering agreement with eurofins discovery, providing eurofin’s global clients’ integrated access to ipa’s end-to-end discovery service financial results revenue the company achieved record revenues of $19.4 million during the year ended april 30, 2022, compared to $17.9 million in fiscal year 2021, an 8.1% increase. the continued growth trend is primarily from project revenues in the company’s b cell select® platform with expansion in both the number and size of projects under contract. for the three months period ending april 30, 2022, the company achieved record revenues of $5.2 million compared to $4.9 million for the three months period ended april 30, 2021, a 7.4% increase. research & development research and development increased to $6.7 million from $2 million in 2021, due to the strategic investment in r&d the company is undertaking, including the company’s sarscov-2 polytope® cocktail and other research projects. net loss the company recorded a net loss of $16.7 million during the year ended april 30, 2022, compared to a net loss of $7.3 million for the year ended april 30, 2021. the $9.4 million increased net loss is primarily due to the company’s investment in r&d, increased professional and consulting fees, increased insurance costs, increased salaries, and benefits to support the company’s strategic plans and operations, and lower grant and subsidy income. liquidity and capital resources as of april 30, 2022, the company held cash of $30.0 million as compared to $41.8 million as of april 30, 2021, and had working capital of $28.2 million. the company’s internal forecast indicates the cash on hand will sustain its existing operations, support its nasdaq and tsxv on-going listing costs and satisfy its obligations for at least 12 months. on october 13, 2021, at at-the-market (“atm”) equity offering facility, was entered into with h.c. wainwright & co., llc, as sole sales agent (“agent”). the company will be entitled, at its discretion and from time-to-time during the term of the atm agreement, to sell through the agent common shares of the company having an aggregate gross sales price of up to us $50 million. as of july 29, 2022, us $50 million of the company’s stock remained available for sale under the atm facility. conference call: date: friday, july 29, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/831812822 the conference call will be webcast live and available for replay via the same link found on the main page of the company’s investors section at: https://www.immunoprecise.com/investors. if you are dialing into the call, please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company’s periodic reports on file with the toronto stock exchange and securities and exchange commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.immunoprecise.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of ipa’s polytope monoclonal antibodies, including tatx-03, to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment, to retain efficacy over time, and to reduce or suppress the emergence of novel variants as well as its potential to prevent the spread of variants. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in developing its polytope monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. *non-ifrs financial measure readers are cautioned that “adjusted ebitda” is a measure not recognized under ifrs. adjusted ebitda is defined as operating earnings before interest, accretion, taxes, depreciation, amortization, share-based compensation, foreign exchange gain/loss, and asset impairment charges. management believes adjusted ebitda is a useful measure that facilitates period-to-period operating comparisons. readers are cautioned that “adjusted ebitda” is not an alternative to measures determined in accordance with ifrs and should not, on its own, be construed as indicator of performance, cash flow or profitability. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release.

the company to host an earnings conference call via webcast victoria, british columbia (canada), july 26, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on friday, july 29, 2022, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. immunoprecise management will host the conference call followed by a pre-submitted question-and-answer period. investors interested in submitting questions ahead of the call are encouraged to email the company’s investor relations contact. conference call: date: friday, july 29, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/831812822 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company’s periodic reports on file with the toronto stock exchange and securities and exchange commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.immunoprecise.com. investor contact: investors@immunoprecise.com

milestone ipa toxicity study supports the safety of polytope® tatx-03 antibody cocktail against covid-19 ind-enabling safety evaluations of polytope® tatx-03, executed under good laboratory practice (glp) standards and regulatory guidelines, revealed no in vivo adverse effects during histopathological examination nor any undesirable off-target binding to human biomaterials. victoria, british columbia (canada), july 12, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, reports the critical third-party findings of two ind-enabling pre-clinical safety studies, de-risking the clinical development of the company’s polytope® tatx-03 antibody cocktail and its potential to prevent and treat covid-19. a summary of the positive findings indicates that, through ex vivo screenings, no non-specific binding of tatx-03 components to human tissues was identified. in addition, an extended pre-clinical in vivo toxicology study did not reveal any tissue or organ changes following exposure to the antibody cocktail, even when administered at over three times the highest anticipated dose in humans. in the current landscape of “not if, but when” people will contract covid-19, the debilitating post-covid “long-haul” effects, and the ongoing life-threatening risks for immunocompromised individuals, this long-awaited safety data illustrates the company’s reputation for uncompromising scientific standards and dedication to sustainable biotherapeutic solutions. the toxicology study was carried out under regulatory-compliant glp conditions with animals receiving three intravenous injections at one-week intervals with either polytope® tatx-03 or placebo. no mortality was observed and, importantly, no macro- or microscopic morphological or histopathological impact was detected on any of the examined organs and tissues even after an extended observation period, as recommended by the fda. in parallel, a full tissue cross-reactivity (tcr) study was performed according to regulatory guidelines and involved colorimetric immunohistochemical analysis of 37 tissue and blood materials from five unrelated humans to cover a broad array of various human tissues, organs and expressed proteins. these screenings did not show cross-reactivity of the individual tatx-03 antibodies, an outcome that supports the specificity of the antibodies to its intended target and suggests that no unintended binding is expected in humans. the toxicology and tcr study results are in line and compliant with the outcomes and conclusions from the previous in vivo pharmacokinetic study, and the dose-escalation study as reported in the company’s march 9, 2022, news release. the positive results reported here will be included in the regulatory filing for approval of clinical studies in humans. “this is another significant milestone for ipa and a leading contribution in efforts to protect against the present and future threat that covid-19 and its variants still pose. these data support the safety of tatx-03 on top of its already demonstrated, and we believe, unprecedented, resilience, reflected by its potency to neutralize all sars-cov-2 variants of concern tested so far,” stated dr. ilse roodink, cso of ipa. “we are confident about the next steps in the program and are compiling the data for sharing with the health authorities for clinical approval,” she continued, “these excellent data readouts on safety and pharmacokinetics tremendously support our ambition to start the first-in-human clinical phase trial which is expected to commence later this year.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.immunoprecise.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete its pre-regulatory approval studies, the ability of the company to successfully submit a clinical use application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely submission of an application for regulatory approval, developing its polytope® tatx-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of polytope® tatx-03, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

ipa subsidiary biostrand receives grant to expand lensai platform by linking hyfts™ with 3d protein structure and function diepenbeek, (belgium), may 9, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to share that ipa’s subsidiary biostrand, a belgian end-to-end multi-omics analysis platform provider, has received a €460,000 round of grant funding from vlaio (flanders innovation & entrepreneurship), the research fund of the flemish regional government in belgium. conditionally awarded in january this year, biostrand recently satisfied the remaining criteria for the award, which follows an original grant from vlaio of €235,000 in 2020. commenting on the latest grant, dr. ingrid brands, general manager and co-founder of biostrand, stated, “thus far, our patented hyft™-based methodology has been applied predominantly to streamline analysis at the syntactic level and combines sequence information with natural language processing. using the presence, occurrence, and distribution of hyft™ patterns, the focus has been on analysis and integration of sequence-based ‘syntactical’ information. we are now extending the methodology to combine syntactical and structural information and to expand our services portfolio with hyft™-based structural and functional modelling functionalities. by linking hyfts™ with the 3d structure (and function) of proteins and expanding platform capabilities for ai discovery, we will be able to support an even wider array of applications, including assay development, biomarker discovery, and computer-aided drug design.” the strategic objective driving this hyft™-based synthesis of syntactical and structural information is to extend biostrand’s technology to encompass the structure of proteins. a key advantage of this blended approach is the detection of protein sequences with similar structures (and function) but without high sequence similarity (distant homologs). a primary application for this approach will be in protein structure prediction, with a particular first focus on antibodies as well as g protein coupled receptors (gpcrs). this will be extended to cover protein-protein interaction prediction (ppi) at a later stage. biostrand is also working on an ai discovery platform that will leverage advanced ai techniques to facilitate integrated protein structure and function analysis. combined with existing r&r and variant analyzer modules, natural language analysis capabilities and the hyft™-based unified syntactical plus structural methodology, biostrand’s ai discovery platform will empower researchers to fully analyse their data and gain insights across the entire analysis pipeline, from raw sequencing data to biologically relevant aspects such as diagnostics and drug discovery. the expansion of biostrand’s omics platform with these advanced functionalities is crucial to become an ambitious market player and position biostrand as a one-stop-shop for omics analysis,” said dr. brands. “we believe that integrating sequence and 3d structure analysis in combination with natural language processing will revolutionize protein structure and function prediction and boost developments in biotechnology and precision medicine. providing a powerful, integrated, and user-friendly data analysis platform for life sciences researchers is our contribution to ramping up the effectiveness of r&d cycles and enabling the real-time analysis of actionable patient data that will bring precision medicine to the next level. it also takes us one step further in our mission to create a truly effective omics data analysis solution.” the company also announces the departure of stefan lang, chief business officer of ipa, effective immediately, and wishes him the best in his future endeavors. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. investor contact: email: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified using words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete the studies proposed for the grant award. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). furthermore, there can be no assurance that the pending patent applications will issue as patents and that challenges will not be instituted against the validity or enforceability of such patents. should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

• ipa’s polytope® tatx-03 shows continuous validation of potent in vitro neutralizing activity against sars-cov-2 variants of concern, as further demonstrated against the omicron sublineage ba.2 • neutralization potency of the tatx-03 cocktail towards ba.2-pseudotyped viral particles is comparable to its previously reported neutralizing activity against omicron ba.1 •in addition to retained potent neutralization by the cocktail as a whole, all four individual therapeutic antibodies in ipa’s tatx-03 retained binding to the ba.2 spike trimer, with reactivity profiles similar to ba.1 victoria, british columbia (canada), april 20, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to share the outcome of recent laboratory data on their polytope® tatx-03 antibody cocktail, which demonstrates strong neutralizing activity toward the omicron subvariant ba.2. the ba.2 pseudovirus was neutralized with a potency comparable to the previously analyzed omicron ba.1, demonstrating ongoing and continued consistency of the cocktail to potently neutralize sars-cov-2 variants of concern (voc). this functional outcome was supported by demonstrated binding of each individual antibody constituent to spike-protein trimer ba.2, data which is also highly comparable with the binding observed against ba.1. various sublineages were identified relatively soon after the sars-cov-2 omicron variant was designated as a voc. of the sublineages classified, ba.2 and ba.3 have higher transmission potential than, for example, ba.1. given the global prevalence and exceptional transmissibility of ba.2, as well as the reality that most antibody therapies authorized by the fda under emergency use authorization have lost neutralizing potency against the omicron variants, recent conversations with the food and drug administration led to prioritizing potency screening of ipa’s tatx-03 product toward ba.2. in line with recent in silico modelling predictions at ipa, the in vitro experimental data showed no significant difference in tatx-03 antibody binding to omicron and the ba.2 sublineage. as anticipated, ipa’s rationally designed anti-sars-cov-2 cocktail potently prevented cell infection by omicron sublineage ba.2 pseudovirus particles at similar antibody concentrations compared to ba.1, resulting in complete neutralization of this dominant subvariant. “in our news release on january 31st, we announced data demonstrating the potent neutralization of the omicron ba.1 subvariant by ipa’s polytope® tatx-03. once again, the remarkable and unprecedented endurance of our first-generation tatx-03 antibody cocktail demonstrates a unique ability to maintain neutralization potency against all concerning viral mutants, this time against the currently dominant omicron sublineage ba.2 containing, yet again, unique mutations,” stated dr. ilse roodink, cso of ipa. “with the new results on the ba.2 subvariant, the vast data package on ipa’s tatx-03 pharmaceutical continues to mount, demonstrating limited variation in its powerful and consistent neutralization potency against all virus variants, giving great confidence to the significance of this resilient product. this is, again, a wonderful confirmation of the sustainability and long-term value of our tatx-03 therapy.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. investor contact: lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete its pre-ind studies, the ability of the company to successfully submit an ind application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely completing its pre-ind studies or submitting an ind application to the fda, developing its polytope® monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, including polytope® tatx-03 and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope® antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). furthermore, there can be no assurance that the pending patent applications will issue as patents and that challenges will not be instituted against the validity or enforceability of such patents. should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

victoria, british columbia (canada), april 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to announce that it has completed its previously announced acquisition of control over biostrand bv, biokey bv, and bioclue bv (hereinafter collectively referred to as “biostrand“), a group of belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary immunoprecise netherlands bv. “uniting biostrand and ipa reflects the company’s commitment to acquiring truly transformative technologies that leapfrog traditional competencies driving the development of safe and effective antibody therapies. for several years ipa’s team has scrutinized artificial intelligence (ai) and machine learning technologies, in search of capabilities that don’t simply give a nod to an opaque use of computationally-driven analyses, nor incremental and limited additions to currently existing research tools, but instead change the trajectory of personalized medicines and the philosophy behind what is truly meaningful for the future of ai in the life sciences,” commented dr. jennifer bath, ceo of ipa. “with biostrand joining the ipa family, we rewrite the future of biotherapeutic discovery, providing access to unique and rapid in silico technologies that unequivocally improve the specificity and design of biotherapeutics,” dr. bath continued. “this is achieved, in part, using patent-pending technologies that identify, define, and code finite and unique fingerprints representing structures and functions present in all omic data. together, we share a common vision and unique strengths using the power of rapidly analyzed genomic, transcriptomic, and proteomic data, combined with natural language processing, to understand the structural and functional basis of diseases, and to develop life-saving precision medicines. our combined capabilities move us closer to more precise and powerful individualized therapies with an aim of changing the way therapies are designed, approved, and prescribed.“ details of the transaction immunoprecise netherlands bv acquired all of the issued and outstanding shares of idea family bv, a private limited liability company holding 75.01% of the issued and outstanding shares of biostrand, as well as the remaining 24.99% of the issued and outstanding shares of biostrand. at closing, the company paid a consideration of approximately € 20 million to the vendors, namely charmquark een, a partnership (maatschap) controlled by dirk van hyfte, charmquark twee, a partnership (maatschap) controlled by ingrid brands, and k&e bv, a private limited liability company (besloten vennootschap) controlled by koen quaghebeur and els paesmans. the consideration consisted of an aggregate of 4,077,774 common shares of ipa, representing approximately € 16,265,500 based on the thirty-day volume-weighted average price of the common shares ending on the trading day immediately prior to the closing; and a cash payment of approximately € 3,734,500 the consideration also includes a contingent earnout payment based on the profitability of biostrand over a 7-year period, which shall not exceed in total €12 million. an investment consideration will also be provided by ipa to biostrand in an aggregate amount of € 6 million over a period of 3 years, for operation expenses, development of biostrand’s platform, and correction of deficiencies. the common shares issued are subject to a statutory resale restriction pursuant to canadian securities laws, as well as a contractual escrow agreement entered into on closing between the vendors, ipa, and an escrow agent, providing for the gradual release of the common shares over a 3-year period. each of biostrand and its securityholders are arm’s length parties to the company. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. about biostrand bv, biokey bv, and bioclue bv\ biostrand, biokey, and bioclue are private limited liability companies, incorporated under the laws of belgium, and are active in the field of bioinformatics and biotechnology. biostrand’s focus is on handling of biological sequences, and generating biological sequence information, software development, algorithms, data visualization and visual analytics. potential applications are in the field of molecular diagnostics, point of care testing, in depth analysis for drug development, prediction, construction and adaptation of biopolymer sequences as well as a product, service, or tool which stores this information in a database. the business of biokey is related to the identification of characteristic biological sequences in proteins, rna and dna, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences. bioclue focuses on technology for performing secondary analysis, consisting of read mapping / assembly and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, rna and dna, including through mass spectrometry, sequencing, microarray or hybrid microarray system technologies. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the launch of sequencing technologies and in silico discovery platforms and expectations regarding the impacts thereof, the contingent earn-out consideration, the form and use of the investment consideration provided by ipa to biostrand, expectations regarding synergies from the transaction and the ability to integrate biostrand into the company’s business, and the projected impact of completion of the transaction on the company’s business, financial conditions and results. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no. 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies investor contact lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com

new platform integrates sequence data and information from entire biosphere • acquisition includes wholly owned subsidiary businesses biokey bv and bioclue bv. • platform is based on a proprietary biological discovery called hyft™ patterns, signature sequences in dna, rna, and amino acids. • the hyfts information model combined with advanced artificial intelligence (ai) creates new comprehensive high speed analysis capabilities while maintaining high accuracy and reducing computational footprint. • novel ai-powered protein-protein interactions prediction platform. victoria, british columbia (canada), march 29th, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to announce that it has entered into a definitive share purchase agreement (spa) to acquire, through its wholly-owned subsidiary immunoprecise netherlands bv, control over biostrand bv, biokey bv, and bioclue bv (hereinafter collectively referred to as “biostrand”), a group of belgian biotech entities and pioneers in the field of bioinformatics and biotechnology. this transaction is expected to create short and long-term commercialization opportunities with clients and partners by introducing a novel ai-powered protein-protein interactions prediction platform and fortifying ipa’s sequencing with massive throughput capabilities in omics (genomics, transcriptomics, proteomics, and metabolomics) interrogation. the company anticipates that the transaction will not only attract new clients and partners but will also enable its subsidiary, talem therapeutics, to access unparalleled ai technologies to help power each stage of its therapeutic antibody development. transaction highlights • biostrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis. • the acquisition enhances ipa’s position as a leader in the field of biotherapeutics – biostrand’s software and ai capabilities complement every sector of ipa’s business. • biostrand’s semantically driven natural language process (nlp) approach makes omics data research truly effective and differentiates ipa’s offerings to provide a powerful and unique opportunity for ipa’s clients. • total consideration of € 20 million, of which € 2 million will be paid in cash, subject to adjustments, and € 18 million will be paid in equity. • management and board of directors unanimously approved the transaction. differentiating technologies biostrand offers an ai-powered revolutionary methodology for rapidly analyzing and mining a broad range of biological data to identify patterns and variations in multi-omics data and detect structural anchor points that will drive innovation in numerous fields including precision medicine, drug and vaccine development, and target discovery. by detecting hyfts™, which are proprietary biological signature sequences, multiple layers of information in sequence and structural data are automatically integrated, resulting in a systems approach to omic analyses. these hyfttm fingerprints connect sequences and literature analysis through a bottom-up nlp approach, by providing a universal syntax for the language of biology. this revolutionizing pattern and profile detection is critical in understanding diseases and biological processes. multi-omics data integration typically requires quite considerable expertise in computational techniques with additional challenges in accuracy and reliability. with biostrand’s revolutionary hyft™ framework, all biological data is instantly computable. company synergies the acquisition of biostrand expands ipa’s scientific capabilities to excel far beyond antibody discovery, expanding from the earliest stages of target identification to late-stage therapies. the transaction combines biostrand’s computer-aided drug discovery capabilities with ipa’s best-in-class antibody discovery and development expertise to create an integrated, next-generation, end-to-end platform for target and therapeutic antibody discovery and development. dr. jennifer bath, president and chief executive officer of immunoprecise antibodies, commented, “the addition of biostrand’s next-generation capabilities in systems omics analysis further enhances ipa’s unique ability to serve as a single-source partner to support our clients’ in silico, in vitro and in vivo research, further solidifying our position as the leading, early-stage antibody discovery contract research organization. a previously undisclosed collaboration with biostrand has already generated unique and intriguing data and we are confident that our clients and partners will find the addition of biostrand’s offerings both advantageous and transformational for their research programs. we believe the acquisition of biostrand, recently referred to as the “google of genomics”, is a blockbuster move, brings together a revolutionary combination that will change the way researchers approach and complete target and antibody discovery, and that our combined platforms, once integrated, will attract new business opportunities at an accelerated rate. we are excited to add biostrand to the ipa family.” the transaction pursuant to the spa, immunoprecise netherlands b.v. will acquire i) all of the issued and outstanding shares of idea family bv, a private limited liability company holding 75.01% of the issued and outstanding shares of biostrand and ii) the remaining 24.99% of the issued and outstanding shares of biostrand, the whole for a total consideration of approximately € 20 million, plus a potential earnout consideration. the purchase price will be satisfied as follows: • approximately € 2 million payable in cash, of which € 1 million will be subject to holdback. a sum of € 500,000 will be held back for a period of 90 days after closing of the transaction for adjustment purposes and € 500,000 of the cash consideration will be held back and progressively released over a 3-year period to guarantee the obligations of the vendors under the spa; • a number of common shares of ipa to be issued at closing, the value per common share to be determined based on the 30-day volume-weighted average price of the common shares (vwap) ending on the trading day immediately prior to the date of closing, representing no greater than 19.99% of the issued and outstanding common shares of ipa immediately prior to closing, for an aggregate deemed value of € 18 million. in the event the issuance cap is reached, ipa will make a cash payment to the vendors equal to the value of the common shares that were not issued as a result of the issuance cap, based on the vwap of the common shares as of the closing date; and • a contingent earnout payment based on the profitability of biostrand over a 7-year period, which shall not exceed in total € 12 million. other key deal terms • biostrand is being acquired on a debt-free, cash-free basis; • investment consideration provided by ipa to biostrand of aggregate amount of € 6 million in the form of a loan or in the form of equity over a period of 3 years for operation expenses, development of biostrand’s platform, and correction of deficiencies; • customary representations and warranties in the spa; • customary indemnities for breaches of representations and warranties and breaches of covenants in the spa; • the equity consideration will be subject to a 4-month statutory resale restriction period pursuant to canadian securities laws, as well as a contractual escrow agreement to be entered into at closing between the vendors, ipa, and an escrow agent, providing for the gradual release of the common shares over a 3-year period. • key personnel, including the founders of biostrand and other members of the executive team of biostrand, will continue their employment with updated management agreements; • non-competition and non-solicitation agreements will be entered into, as a condition of closing, with certain principals of biostrand; • each of biostrand and the biostrand shareholders are arm’s length parties to the company; • the purchase price is subject to working capital and other adjustments; • closing of the transaction is expected to occur on or before april 15, 2022, subject to receipt of all applicable approvals and the satisfaction of applicable conditions to closing; • the other closing conditions in the spa are customary, including, but not limited to, the receipt of all necessary regulatory approvals and the required notifications to nasdaq with respect to the issuance of ipa’s common shares; and • the transaction is an “expedited acquisition” under policy 5.3 of the tsx venture exchange. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. about biostrand bv biostrand bv is a private limited liability company, incorporated under the laws of belgium. the business of biostrand bv focuses on technology, in the field of bioinformatics and biotechnology, for handling of biological sequences including for example processing, storing and comparing biological sequence information, and for generating biological sequence information, software development, algorithms, data visualisation and visual analytics, which can for example be applied in the field of molecular diagnostics, point of care testing, in depth analysis for drug development, prediction, construction and adaptation of biopolymer sequences as well as a product, service, or tool which stores this information in a database. about biokey bv biokey bv is a private limited liability company, incorporated under the laws of belgium. the business of biokey bv focuses on technology, in the field of bioinformatics and biotechnology, related to the identification of characteristic biological sequences in proteins, rna and dna, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences. about bioclue bv bioclue bv is a private limited liability company, incorporated under the laws of belgium. the business of bioclue bv focuses on technology, in the field of bioinformatics and biotechnology, for performing, inherently linked with a microarray process and possible primary analysis, a secondary analysis, whether or not performed simultaneously with the primary analysis, consisting of read mapping, read assembly – de novo or reference based – and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, rna and dna, including through mass spectrometry, sequencing, micro array or hybrid microarray system technologies. investor contact: lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the transaction, expectations regarding synergies from the transaction and the ability to integrate biostrand into the company’s business, pro forma financial estimates, including revenue, the opportunities presented by the transaction, synergies and expansion opportunities, the expansion of the company’s knowledge lifecycle, the expected closing of the transaction, the receipt of all necessary regulatory approvals and satisfaction of all other closing conditions and the projected impact of completion of the transaction on the company’s business, financial conditions and results. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely completing the transaction, the necessary approvals are not obtained or some other condition to the closing of the transaction is not satisfied, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no. 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. there is no guarantee that the transaction will close at all, or in the time frame anticipated, or on the terms as originally negotiated. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies